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1. Introduction
In 1948, it was discovered that cytotoxic 
folate antimetabolites could treat child-
hood leukemia[1] and the basic approach 
for cancer therapy has remained the 
same way: surgery followed by chemo-
therapy with various cytotoxic compounds 
or radiation.[2] Conventional cytotoxic 
chemotherapy usually kills dividing cells 
rapidly in the body by interfering with 
cell division. However, commonly used 
chemotherapy drugs have poor selectivity, 
which not only kill tumor cells but also 
damage normal cells and tissues, causing 
serious toxicity and side effects such as 
myelosuppression, nausea, vomiting, hair 
loss, and reduced fertility.[3] The intrinsic 
limits of conventional cancer therapies 
like insufficiency in water solubility of 
drugs, drug resistance after repeated 
administration, and off-targeting to cancer 
cells make it difficult to cure cancer.[4] 
Advantages such as strong signal strength, resistance to photobleaching, 
tunable fluorescence emissions, high sensitivity, and biocompatibility are 
the driving forces for the application of fluorescent nanoparticles (FNPs) in 
cancer diagnosis and therapy. In addition, the large surface area and easy 
modification of FNPs provide a platform for the design of multifunctional 
nanoparticles (MFNPs) for tumor targeting, diagnosis, and treatment. In 
order to obtain better targeting and therapeutic effects, it is necessary to 
understand the properties and targeting mechanisms of FNPs, which are 
the foundation and play a key role in the targeting design of nanoparticles 
(NPs). Widely accepted and applied targeting mechanisms such as enhanced 
permeability and retention (EPR) effect, active targeting, and tumor 
microenvironment (TME) targeting are summarized here. Additionally, a 
freshly discovered targeting mechanism is introduced, termed cell membrane 
permeability targeting (CMPT), which improves the tumor-targeting rate 
from less than 5% of the EPR effect to more than 50%. A new design strategy 
is also summarized, which is promising for future clinical targeting NPs/
nanomedicines design. The targeting mechanism and design strategy will 
inspire new insights and thoughts on targeting design and will speed up 
precision medicine and contribute to cancer therapy and early diagnosis.
Fluorescent Nanoparticles
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The advent of “targeted” cancer therapies changed the situa-
tion. The targeted nanomedicines prompt the growing inter-
ests in the applying of nanotechnology in the cancer diagnosis 
and therapy.[5] The major goal of targeted therapies is to fight 
cancer cells more accurately with fewer potential side effects.[6] 
With the continuous development and progress of imaging 
technology in spatial and temporal resolution, scientists can 
detect the activity of tumors and deep tissues of body through 
live imaging. It is obvious that the targeting imaging of tumors 
has a great significance for cancer diagnosis and treatment. 
Nowadays, various biomedical imaging technologies are 
blooming, and they have become accurate and powerful tools 
in clinical diagnosis and therapy assessment for cancer. They 
provide a noninvasive, highly sensitive, and specific observa-
tion way for identifying and monitoring the pathological and 
physiological events associated with human cancer.[7,8] For 
instance, fluorescence imaging (FI), computed tomography 
(CT), photoacoustic imaging (PAI), ultrasound imaging (USI), 
positron emission tomography (PET), magnetic resonance 
imaging (MRI), photothermal imaging (PTI), and Raman 
imaging (RI) have been well developed and play a great role 
in preclinical and clinical practice.[7–9] Compared with other 
technologies, FI technology has many advantages such as the 
high sensitivity, noninvasive, and real-time safe detection, and 
readily available instrumentation.[10] It is quite obvious that the 
targeting imaging of tumors has a great significance for cancer 
diagnosis and treatment. Compared with radioisotope labe-
ling, MRI, electrochemical detection, and other technologies, 
FI technology has many advantages such as the highly sen-
sitivity, noninvasive, and real-time safe detection and readily 
available instruments.[10] Using fluorescent dyes conjugated 
with specific targeting molecules that are able to bind with the 
receptors overexpressed in malignancy can specifically target 
to malignant tumors and distinguish tumor from normal tis-
sues, which has obvious advantages for the early diagnosis and 
accurate surgical resection of malignant tumors.[11] Fluorescent 
dyes including fluorescein, rhodamine, cyanine, and so on are 
widely recognized as one of the simple and effective methods 
for labeling tumor cells.[10] However, fluorescent dyes have the 
disadvantages of high toxicity, poor photostability, low quantum 
yield, and short fluorescent lifetime etc.[12] Along with the 
great progress in the field of nanotechnology, many classes of 
nanomaterials (organic, inorganic, and metallic) are currently 
employed as fluorescent emitters, called FNPs.[13] Compared 
to conventional fluorescent dyes, FNPs have stronger fluores-
cent brightness, better photostability, water dispersibility, and 
biocompatibility, which enable FNPs to meet the requirements 
for cancer therapy and diagnosis application fields. FNPs 
offer a multifunctional platform for tumor targeting diag-
nosis, therapy and show special superiority, shining on the 
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battle against cancer, which has aroused great concern in 
recent years.[14,15] Moreover, the complexity and heterogeneity 
of tumors require to choose the applicable FNPs and effec-
tive targeting strategies.[16] Among this big family of FNPs, 
there are mainly five types of nanomaterials: fluorescent dye-
doped nanoparticles (FL dye-doped NPs),[13,17] semiconductors 
quantum dots (QDs),[18,19] metal nanoclusters (MNCs),[20] rare 
earth NPs,[21,22] and fluorescent carbon-based nanomaterials 
(FCNMs).[23,24]
As mentioned above, there are some disadvantages of 
fluorescent dyes that can be overcome by using nanocarriers. 
Nanocarriers can carry a large amount of fluorescent dyes 
inside by embedding, covalent linkage, or absorption etc., pro-
tecting the fluorescent dyes from being destroyed to improve 
the photo stability and emit stronger fluorescence.[25] Silica NPs 
labeled with fluorescent dyes are one of the most widely used 
nanocarriers for cancer bioimaging and theranostic applica-
tions.[13,26] However, nanomaterials without autofluorescence 
can only act as a carrier with disadvantages of large cytotoxicity 
from surfactant and leakage of fluorescent dyes, which limits 
their application. Therefore, intrinsically luminous FNPs, such 
as QDs, MNCs, upconversion nanoparticles (UCNPs), and 
FCNMs are extensively studied. QDs are kind of ultrasmall 
semiconductor NPs, only several nanometers in size. Most of 
them composed of elements from groups II to VI, III to IV, 
or IV to VI from the periodic table. Such a small size gives 
them excellent optical and biological properties in molecular 
imaging and biomedical diagnostics.[18] Notably, QDs have a 
broad absorption spectrum and a narrow emission spectrum 
with strong antiphotobleaching, long fluorescence lifetime, and 
extensive tunable size.[27,28] Extensive research during the past 
more than 30 years have been developed to get the high-quality 
and water-soluble QDs probes for biology and nanomedicine 
applications since it was first reported in 1983.[28,29] However, 
the in vivo toxicity triggered by the particle and the subsequent 
release of toxic metals and ions greatly limits theirs biological 
applications.[30] Recent advances in nanotechnology have given 
rise to a new class of FNPs called MNCs, e.g., AuNCs, AgNCs, 
and CuNCs, whose diameters are below 2 nm, composed of 
several hundreds of metal atoms in a transition state between a 
single metal atom and a larger metal nanoparticles (MNPs).[31] 
Compared with larger MNPs, it has a lot of unique physico-
chemical properties, such as adjustable fluorescent emission, 
large stokes shift, high fluorescent stability, and high quantum 
yield, etc.[32] In contrast to conventional fluorophores and QDs, 
the toxicity of MNCs is reduced greatly and the biocompatibility 
of MNCs is significantly improved.[32] Therefore, they are widely 
used for bioimaging and cancer diagnosis and treatment as a 
new type of nanofluorescent probe.[33] Another one of the most 
active fields of research in the past decades is the development 
of rare-earth-doped nanoparticles with unique optical proper-
ties.[22,34] Among the most widely used are UCNPs usually 
synthesized with host lattices such as LaF3, YF3, Y2O3, LaPO4, 
NaYF4 doped with trivalent rare earth ions such as Yb3+, Er3+, 
Tm3+, etc.[21] In addition to the above materials, FCNMs is also 
a promising type of nanomaterials that are applied in biological 
fields, which includes carbon dots (CDs), graphene quantum 
dots (GQDs), polymer dots (PDs), and luminescent nanodia-
monds (NDs).[35] The low toxicity and good biocompatibility of 
FCNMs make it an excellent substitute for semiconductor QDs. 
Along with enormous progress in the field of cancer nano-
medicine, all these FNPs have been applied in cancer targeting 
diagnosis and therapy. Some results have demonstrated that 
MFNPs conjugating multiple components such as fluorescent 
molecules, tumor-targeting legends, anticancer drugs, or siRNA 
can achieve multiple functions for the application in targeting 
cancer diagnosis and treatment.[36] Herein, we will focus on 
the main targeting strategies, including the EPR effect, active 
targeting, and TME to claim the application of FNPs in tumor 
targeting application. Beyond that, we will also introduce the 
new targeting strategy called CMPT proposed by Wang’s group, 
which improves the tumor-targeting rate from less than 5% of 
the EPR effect to more than 50%.[37] The CMPT mechanism 
will stimulate new insights for the targeting design, accelerate 
the development of tumor precision medicine, and contribute 
to cancer treatment and early diagnosis.
2. Tumor Targeting Strategies
The targeting property of traditional antineoplastic chemo-
therapy drugs is too poor hampering the distinction between 
normal tissue and tumor tissue. The rapid elimination from 
the circulatory system, systemic toxicity, and side effects are 
the main barriers for the application in cancer.[3] The tar-
geting nanomedicines/nanoparticles design and their targeting 
mechanisms is the way to improve the targeting efficiency and 
lower the side effects. Figure 1 briefly summarizes the current 
research status of tumor targeting strategies .
2.1. Passive Targeting
The passive targeting mainly refers to the EPR effect, which was 
first proposed by Matsumura and Maeda in 1986.[38,39] Maeda 
found that a polymer accumulated in tumor tissues when con-
jugated with the anticancer protein. They also showed that 
many proteins progressively accumulated in the tumor tissues 
in vivo, and a ratio of the protein concentration in the tumor 
to that in the blood of 5 was obtained within 19 to 72 h.[38]  
The fundamental physiological feature of the EPR effect 
is the malformed vasculature coupled with poor lymphatic 
drainage of solid tumors tissues allowing the large particles 
to leak from blood vessels and passively accumulate in the 
tumor sites.[40,41] Traditional small molecule drugs have low 
selectivity and most of such drugs are distributed in normal 
tissues, resulting in severe systemic toxicity. It is obvious that 
systemic adverse effects were reduced and therapeutic effects 
were improved by tumor targeting anticancer drugs nanocar-
rier designing (Figure 2).[42,43] Meanwhile, the concentration of 
macro molecular drugs in tumor tissues is far more than five 
to tenfold, which is very difficult to reach for small molecular 
drugs.[44]
The EPR effect became the “gold standard” for nanoparti-
cles anticancer drug design, including NPs.[45] The EPR effect 
mainly depends on the size, surface properties of the nano-
carriers, and the physiological properties of the tumors. So, to 
achieve optimal targeting and therapeutic efficacy, NPs must 
Adv. Mater. 2019, 31, 1902409
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be designed in the size range of 20–200 nm, which can easily 
extravasate through the malformed tumor vessels, and the 
accumulation in tumors is further enhanced because of poor 
lymphatic drainage.[46] Nanocarriers have several advantages 
over conventional low-molecular-weight drugs including a large 
loading capacity, protecting drugs from degradation, specific 
targeting, and controlled release.[47,48] Furthermore, their phys-
ical and chemical properties can be optimized by changing the 
shape, size, and surface properties.[49] Thus, the fields of nano-
medicine are developed rapidly. Potential advantages of NPs 
include prolonged circulation time of drugs, decreased kidney 
or liver clearance rate, and distribution lead to minimal non-
specific accumulation and enhance therapeutic effect.[50,51] For 
example, large micelles (less than 100 nm) can easily escape 
from renal excretion, but are still small enough to enhance the 
leakage of tumor blood vessels.[52]
Molecular imaging is an excellent method for visual moni-
toring of cellular processes. By monitoring probes in vivo, mole-
cular dynamics in cells are tracked. Therefore, visual diagnosis is 
great significant in medicine and clinic.[28,53] In recent years, an 
increasing number of FNPs are used to improve the cancer diag-
nostic and therapeutic imaging, primarily for preoperative and 
Adv. Mater. 2019, 31, 1902409
Figure 2. The process of FTNPs targeting to tumor through EPR effect and therapy effect. RES: reticuloendothelial system, IFP: tumor interstitial 
pressure, ROS: reactive oxygen species.
Figure 1. Schematic illustration of tumor targeting strategies. EPR: enhanced permeability and retention effect, TME: tumor microenvironment, CMPT: 
cell membrane permeability targeting mechanism. Image for CMPT: Adapted with permission.[37] Copyright 2019, Wiley-VCH. TAF: tumor associated 
fibroblasts, TAM: tumor associated macrophage, TAN: tumor associated neutrophils, MDSCs: myeloid-derived suppressor cells, TIL: tumor-infiltrating 
lymphocytes, ECM: extracellular matrix.
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intraoperative FI observation.[54] There have been many reports 
about the FNPs designed based on EPR effect for visual targeting 
imaging.
2.1.1. Fluorescent Dye-Doped NPs
NPs combined with fluorescent dyes for imaging are a common 
strategy. It is an excellent way to produce enhanced fluorescent 
signals by selecting suitable NPs and modifying the surface with 
fluorescent dyes.[55] A variety of NPs have been used including 
silica NPs,[56] chitosan NPs,[57] iron oxide NPs,[58] AuNCs,[59] 
and calcium phosphate NPs,[60] and so on. Primarily, organic-
based fluorescent dyes are used, for example, indocyanine 
green (ICG),[60,61] Cy5, or Cy5.5,[58,62] fluorescein isothiocyanate 
(FITC),[63] etc. Zhang et al. synthesized a new type of metaboliz-
able and efficient radiosensitizers for cancer radiotherapy, which 
combined ultrasmall AuNCs (<2 nm) with biocompatible coating 
ligands (glutathione, GSH). They labeled the new Au25NCs with 
Cy5 for FI. As shown in the result of in vivo experiment, the 
Au25NCs displayed higher tumor accumulation via the improved 
EPR effect and had a better cancer therapeutic effect.[59] Altinoglu 
et al. studied the EPR effect in nude mice implanted with subcu-
taneous human breast adenocarcinoma tumors by ICG-doped 
calcium phosphate NPs (CPNPs). Their results showed that 
PEGylated CPNPs encapsulation prolonged circulation time 
in vivo due to the EPR effect. The CPNPs was still visible even 
more than 96 h postinjection. Moreover, the ICG-CPNP dis-
played deeper penetration capacity than free fluorophore.[60]
2.1.2. Quantum Dots
QDs are also known as semiconductor nanocrystals with an 
approximate spherical shape. Its 3D size ranges from 2 to 
10 nm with obvious quantum effects resulting in unique optical 
and electrical properties, especially strong photoluminescence, 
high sensitivity, and good stability. Fluorescent QDs have tun-
able fluorescent emission spectrum from visible to infrared 
wavelengths, large absorption coefficient across wide spectrum 
range, and very high optical stability.[55,64] However, cytotoxicity 
related to heavy metals remains a hot topic and limit for future 
bioimaging applications of QDs.[55] The advent of GQDs seems 
likely to solve the problem. GQDs have been found to exhibit 
better biocompatibility, lower toxicity, and better photostability 
against photobleaching and blinking.[65]
QDs seem too small for the EPR effect, but researchers 
have come up with some strategies. NPs with diameter of 
about 100 nm showed good EPR effect of tumor accumula-
tion, but their large size hinders penetration into the dense 
collagen matrix. Wong et al.[66] presented a multistage system, 
in which the size decreased from 100 to 10 nm after leakage 
from tumor vessels to tumor microenvironment (TME). They 
used QDs as a model to test whether it was feasible. They uti-
lized collagen gel to simulate the interstitial matrix of a solid 
tumor. The two kinds of designed experimental QDs (silica 
QDs and QDs Gel NPs) before or after cleaving were placed in 
contact with the gel and incubated for 12 h. The results indi-
cated that both silica QDs and QDs Gel NPs have negligible 
permeability before cleaving and were excluded from collagen 
matrix. However, after cleavage of QDs Gel NPs, the freed QDs 
were able to penetrate over a millimeter into the gel. The in 
vivo image indicated that the QDs Gel NPs achieved more accu-
mulation after cleaved.[67] Du et al. synthesized a kind of GQDs 
with an average diameter of 2–5 nm, which increased to about 
10 nm after Chlorin e6 (Ce6) conjugation. The GQDs–SS–Ce6 
had excellent therapeutic effect on nude mice bearing HeLa 
tumor. Effective tumor suppression of GQDs–SS–Ce6 in tumor 
treatment is mainly due to the improved the EPR effect of 
smaller GQDs nanosystem as manifested by the above in vivo 
and ex vivo imaging experiments.[68] QDs have been verified to 
enhance the EPR effect due to the better ability of small size 
penetration in tumor sites,[66,68–70] and some small size GQDs 
can produce singlet oxygen, killing cancer cells.[69,71]
2.1.3. Carbon Nanotubes
Carbon nanotubes (CNTs), including single-walled carbon nano-
tubes (SWNTs) and multiwalled carbon nanotubes (MWNTs), 
have attracted much attention since their discovery in 1990.[72] 
The unique optical properties of CNTs, especially SWNTs, give 
them great potential in the field of biological imaging. SWNTs 
exhibit intrinsic photoluminescence (PL) in the near-infrared 
(NIR) spectrum, within the “biological window” (700–1300 nm) 
where absorption, scattering, and autofluorescence by tissues, 
blood, and water are minimized.[73]
Countless articles have reported the application of SWNTs. 
For example, functional SWNTs can avoid rapid clearance by 
the immune system,[74] and have been used for drug carrier[75] 
and NIR imaging.[76] Liu et al. reported a kind of PEG-function-
alized SWNTs; they detected blood circulation up to 1 day with 
the SWNTs: biliary and renal are the main excretion pathways. 
Their results suggest that increased circulation time contributes to 
increased passive tumor accumulation of EPR effects.[77]
Impurities of MNPs contained in CNTs samples can be utilized 
for MRI to provide strong T2-weighted imaging contrast.[78,79] In 
addition, radionuclides can be coupled to and even inserted into 
CNTs to present more imaging modalities, including PET[80] and 
single-photon emission CT.[81] Choi et al. demonstrated for the 
first time the use of the SWNTs/iron oxide NPs complexes as 
multimodal biomedical imaging agents. By encapsulation with 
DNA, the SWNTs/iron oxide NPs complexes are individually dis-
persed in aqueous solution and are more easily introduced into a 
biological environment. The application of the NIR mapping and 
MRI realized the multimodal biomedical imaging.[79]
2.1.4. Au Nanoclusters
The low toxicity, bright NIR fluorescence, and ultrasmall size 
give AuNCs a promising prospects in biomedical application 
field.[82,83] Protein- and peptide-stabilized AuNCs are especially 
suitable for bioimaging and therapy, owing to their unique 
functionality, easy conjugation, biocompatibility, large stokes 
shift, long lifetime, as well as photo and chemical stability.[84] 
Wu et al. showed the possibility of using ultrasmall NIR 
AuNCs for tumor FI in vivo. They first investigated AuNCs in 
Adv. Mater. 2019, 31, 1902409
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living mice and found that the uptake of BSA–AuNCs by the 
reticuloendothelial system (e.g., liver and spleen) is relatively 
low in comparison with other nanomaterials, partly due to 
their ultrasmall hydrodynamic size. Furthermore, by selecting 
MDA-MB-45 and HeLa tumor xenograft models, the EPR effect 
of ultrasmall NIR AuNCs has been demonstrated in tumor-
bearing mice.[82] GSH–AuNCs have been implemented in 
bioimaging to assess biodistribution, renal clearance, pharma-
cokinetics, and tumor accumulation.[85]
2.1.5. The Defects of EPR Effect
Some of the NPs approved by the US Food and Drug Admini-
stration (FDA) such as liposomal doxorubicin (Doxil/Caelyx)[86] 
or daunorubicin citrate liposomes (DaunoXome)[87] have 
reduced the side effects, but only mild improvements have 
been seen in the patient survival rate.[48,88] In fact, the tumor 
targeting efficiency of NPs/nanomedicines designed by the 
EPR mechanism is very low, less than 5%.[43,52,89] Chan et al. 
reviewed more than 100 nanomedicine papers from the past 
10 years, and found that an average of just 0.7% of any NPs 
dose, whether actively targeted or not, gets into tumors.[90] 
There are some reasons for this, resulting in low targeting rates. 
For example, abnormal tumor vasculature, high interstitial 
fluid pressure, growth-induced solid stress, solid stress from 
abnormal stromal matrix, and so on.[52,91] Another problem 
is the pathophysiological heterogeneity of tumors. Different 
tumors vary greatly, especially in the central area of cancer, and 
do not exhibit the EPR effect.[92] Some articles pointed out that 
most of the NPs are accumulated in the liver, spleen, and other 
organs for a long time. The incomplete metabolism will induce 
long-term organ damage.[43,93] Due to the passive targeting 
effect based on the EPR effect being disappointing, the 
researchers have thought and sought other ways to improve 
the specific targeting rate of tumors, such as active targeting, 
the TME, and CMPT etc.
2.2. Active Targeting
For anticancer active targeting, two types of cellular tar-
geting are distinguished: active targeting to cancer cells due 
to the overexpression of transferrin, folate, epidermal growth 
factor (EGF), or glycoproteins and so on and active targeting 
to the tumor endothelium due to the overexpression of the 
vascular endothelial growth factors (VEGF), αvβ3 integrins, 
the vascular cell adhesion molecule-1 (VCAM-1) or matrix 
metalloproteinases (MMP) etc. For targeting approach, it can 
be divided into the following categories: receptor-mediated 
Adv. Mater. 2019, 31, 1902409
Figure 3. Schematic illustration of active targeting. Receptor-mediated targeting: a) FA-Polymer NPs. Reproduced with permission.[96] Copyright 2013, 
Wiley-VCH. b) MRTN. Reproduced with permission.[118] Copyright 2014, Wiley-VCH. c) Cy5.5-PEG-g-A-HA NPs. Reproduced with permission.[127] Copyright 
2018, American Chemical Society. d) FONs-EGF. Reproduced with permission.[132] Copyright 2017, RSC Pub. Peptide-mediated targeting: e) MNPs-Cy5-RGD. 
Reproduced with permission.[134] Copyright 2009, Wiley-VCH. f) TAT-RGD-PEO-b-PCL. Reproduced with permission.[149] Copyright 2011, American Chemical 
Society. g) QDs-PEG-CGKRK. Reproduced with permission.[151] Copyright 2015, Wiley-VCH. h) DOX@UiO-66/Py−PGA-PEG-F3. Reproduced with permis-
sion.[152] Copyright 2017, American Chemical Society. Antibody-mediated targeting: i) QDs-antibody. Reproduced under the terms of the CC-BY Creative 
Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).[157] Copyright 2012, The Authors, Published by PLOS. j) QDs-cetuximab. 
Reproduced with permission.[162] Copyright 2012, Future Medicine Ltd. k) UCNPs-antibody. Reproduced with permission.[167] Copyright 2009, American 
Chemical Society. Aptamer-mediated targeting: l) Pt-PLGA–PEG NPs-Apt. Reproduced with permission.[172] Copyright 2008, National Academy of Sciences. 
m) DNPs-Apt. Reproduced with permission.[173] Copyright 2016, Springer Nature.
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targeting; peptide-mediated targeting; antibody-mediated 
targeting; aptamer-mediated targeting[94] (Figure 3).
2.2.1. Receptor-Mediated Targeting
Receptor-mediated targeting is a common strategy to design 
fluorescent nanocarriers for active targeting to tumors by 
binding the ligands matched to the overexpressed receptors on 
tumors. At present, the most studied receptors that act as active 
target vectors mainly include folate receptors (FR), transferrin 
receptors (TfR), hyaluronic acid receptors (HAR), epidermal 
growth factor receptors (EGFR), etc.[94,95]
FR overexpressed in many cancer types provides an effective 
strategy for targeting to tumors by folic acid (FA) functionalized 
FNPs. Ahmed’s group reported multifunctional polymer NPs 
with fluorescent multiblock for bioimaging and FA for tumor 
targeting (Figure 3a).[96] While Rosenholm et al.,[97] Nakamura 
et al.,[98] and Santiago et al.[99] designed multifunctional silica 
NPs with fluorescent and targeting moieties for specifically 
targeting cancer cells with FA as a targeted ligand for active 
targeting. Liong et al. had also designed the multifunctional 
inorganic NPs conjugated with FA for increasing the uptake of 
hydrophobic anticancer drugs by cancer cells. In addition, it has 
dual-imaging capability of MRI imaging by superparamagnetic 
iron oxide nanocrystals and optical imaging by conjugating 
with FITC. Their result show that the highly versatile MFNPs 
can be used for drug delivery, MRI, and magnetic manipula-
tion, FI and cell targeting simultaneously, with the potential 
for simultaneous imaging and therapeutic applications.[100] Liu 
et al. used black phosphorus nanosheet (BPNS) as a nanocar-
rier functionalized with FA and a DNA aptamer (Apt) for spe-
cific recognition.[101] Modified fluorescent QDs as a targeting 
and delivery system are also potentially effective tools for tumor 
optical imaging, diagnosis, and treatment, which has been 
studied for many years.[102] Besides, Prasad and co-workers[103] 
and Chatterjee et al.[104] have shown a new approach for in vitro 
and in vivo bioimaging utilizing UCNPs about 10 years ago. To 
enhance the tumor selectivity, Hu et al.,[105] Xiong et al.,[106] and 
Cao et al.[107] have developed UCNPs conjugated with FA for 
in vitro and in vivo targeted imaging. In order to improve the 
local effective treatment concentration of drugs and minimize 
toxicity and side effects of patients, researchers have taken a 
variety of approaches to modify the UCNPs for multifunctional 
application, such as targeting bioimaging with FA, drug delivery 
for chemotherapy, and photodynamic therapy (PDT).[108] As 
mentioned above, tumor-specific targeted therapy based on 
FA is one of the most widely applied and important methods. 
However, the expression of FR in normal tissues will lead to 
unexpected results with poor targeting effect and unsatisfactory 
therapeutic effects. Very recently, Yu et al. developed a prepro-
tective strategy using a switchable UCNPs nanocomposite con-
jugated with two types of DNA of different length, shorter DNA 
modified by FA and longer DNA modified by Ce6. In normal 
tissues, FA is protected by longer DNA, which can be triggered 
in tumor site to exposed FA for precise targeting and PDT 
just as shown in Figure 4.[109] As FCNMs are a kind of novel 
fluorescent nanomaterial exhibiting promising applications in 
the biological field, they have attracted plenty of interests to 
combine with FA for active targeting. Such as carbon dots 
(CDs),[110] nanodiamonds (NDs),[111] and GQDs.[112]
TfR is a dimeric transmembrane glycoproteins receptor for 
transferrin, which import iron by receptor-mediated endocytosis 
of transferrin iron complex. Studies have shown that TfR highly 
expressed on the surface of many types of tumor cells.[113] Thus, 
Tf-conjugated FNPs could selectively target to TfR-overexpressed 
tumor cells by match between Tf and TfR.[114] So far, a lot of 
FNPs conjugated with Tf have been studied deeply to improve 
the targeting efficacy. For instance, organically modified silica 
NPs incorporating rhodamine-B,[115] FITC-modified mesoporous 
silica NPs (FMSNs),[116] magnetic nanocarrier based on chitosan 
and rhodamine-B decorated superparamagnetic iron oxide 
NPs (SPIO NPs),[117] multifunctional rattle-type nanoparticles 
(MRTNs) (Figure 3b),[118] fluorescent calcium phosphosilicate 
nano composite particles (CPNPs) dropped of ICG,[119] and liquid 
crystal NPs (LCNPs) incorporated with fluorescent dye.[120] In 
addition to these, Muthu et al. developed advanced theranostic 
micelles conjugated with Tf and ultrabright AuNCs and car-
ried docetaxel (DTX) for simultaneous cancer imaging and 
therapy.[121] Xu et al. designed a dual-targeting carrier of paclitaxel 
based on hyperbranched copolymer NPs conjugated with Tf and 
RGD (arginine–glycine–aspartic acid) peptide, which is also a tar-
geting ligand that will be reviewed in the next section of 2.2.2.[122]
Hyaluronic acid (HA) is a main component of the extracellular 
matrix (ECM) and intercellular substance. HA plays an important 
role in maintaining the structure of the extracellular matrix and 
regulates intracellular activities with a MW (molecular weight) 
less than 80 000.[123] It has tumor targeting and antitumor effect 
through binding to the overexpressed HAR on tumor cell sur-
face, resulting in enhancement of tumor cells internalization. 
It could regulate tumor angiogenesis, tumor metastasis and 
invasion, and increase the drug concentration of lesion area to 
achieve the purpose of targeted therapy.[124] There are four kinds 
of specific HAR: CD44, RHAMM, IVd4, and LEC overexpressed 
on the cell membrane surface. CD44 receptor, a transmembrane 
glycoprotein, is the most important HAR on the cell surface 
and the main site of binding to HA. Liu et al. prepared bilay-
ered NPs decorated by a lipophilic NIR fluorescent dye, stearic 
acid-grafted polyethyleneimine and HA (DiR-PgSHA NPs) for in 
vivo tumor-targeted optical imaging.[125] Li et al. developed intrin-
sically redox-sensitive nanogels based on fluorescent photoclick 
cross-linking with l-cystine dimethacrylamide (MA-Cys-MA) and 
CD44-targeting hyaluronic acid (HA-NGs), showing highly effi-
cient loading and breast tumor-targeted delivery of cytochrome c 
(CC).[126] Meanwhile, Cheng et al. designed Cy5.5-PEG-HA NPs 
combined with cisplatin for selectively targeting tumors therapy 
and fluorescence imaging in vivo (Figure 3c).[127] Cy5.5-PEG-HA 
NPs have clear fluorescence imaging in the body and show an 
effective accumulation at the tumor site.
EGF can stimulate cell growth strongly by binding to its 
receptor (EGFR), resulting in cellular proliferation, differen-
tiation, and survival.[128] The higher expression of EGFR in 
tissues is associated with several cancers.[129] Tseng et al. used 
gelatin NPs (GPs) modified with FITC-biotinylated EGF as 
drug delivery strategy for lung cancer targeting, imaging, and 
treatment via inhalation.[130] Yuan et al. designed dendrimer-
triglycine-EGF NPs for tumor imaging and targeted drug 
delivery.[131] Faucon et al. demonstrated that fluorescent organic 
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NPs (FONPs) covalent attached with EGF at sub-nanomolar con-
centrations could serve as ultrabright targeting probes for breast 
cancer cells based on EGFR-overexpression (Figure 3d).[132]
2.2.2. Peptide-Mediated Targeting
As tumors proliferating, massive new vessels formation must 
occur to supply nutrition for the tumors. As an adhesion 
molecule of cells, integrin αvβ3 is highly expressed in various 
tumor cells and plays an important role in tumor angiogenesis 
and metastasis. Therefore, integrin αvβ3 can be a target for anti-
tumor targeting nanodrugs, showing the effect of inhibiting 
tumor growth, tumor targeting, and drug delivery. Studies have 
confirmed that ligands containing arginine-glycine-aspartic 
acid (RGD) have a high specificity and affinity for integrin αvβ3.
Some scientists prefer FL dye-doped NPs as nanocarriers for 
bioimaging. Drug delivery nanocarriers conjugated with RGD 
as targeting moiety and fluorescent dyes as imaging moiety 
have been demonstrated.[133–136] Lee et al. developed “all-in-one” 
cancer cell-specific probes based on magnetic NPs conjugated 
with siRNAs, targeting moieties RGD, and fluorescent dyes 
Cy5 (MNPs-Cy5-RGD) for simultaneous delivery and multi-
modal imaging (Figure 3e).[134] Akhavan and Ghaderi designed 
rGONM–PEG–Cy7–RGD containing graphene oxide nanoplate-
lets modified with RGD and Cy7 for in vivo tumor targeting 
and FI of human glioblastoma U87MG tumors.[135] Alvero et al. 
developed a PLGA–PEG–RGD nanoplatform modified with 
three different fluorescent dyes of deep infrared (DIR), Cou-
marin-6 (C6) and ICG for visualization of ovarian cancer micro-
metastasis, reducing inadvertent injury in surgery.[136]
Fluorescent QDs have become the focus of many scientists 
due to their unique optical properties. Li et al. used NIR QDs 
as fluorescent probes modified with cyclic RGD to form tumor-
specific bioconjugates for tumor-targeted imaging. According 
to their results, the tumor visualization, identification, and 
resection could be promoted via FI guidance.[137] Zhang et al. 
proved that Ag2S QDs conjugated with specific ligand-RGD 
is a promising NIR-II probe with bright photoluminescence 
and high biocompatibility for targeted labeling and imaging 
of cancer cells.[138] Lu et al. synthesized excellent aqueous 
dispersible near-infrared-emitting QDs (aqQDs) modified 
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Figure 4. a) Precise tumor targeting and specific PDT for cancer of UCNPs@PAA–DNA. b) Confocal images of MCF-7 cells incubated with UCNPs@
PAA–DNA1/2 at pH 6.5 and 7.4. c) In vivo imaging of five major organs harvested from a mouse at 8 h postinjection with UCNPs@PAA–DNA1(Ce6) 
(left) or UCNPs@PAA–DNA1/2 (right). a–c) Reproduced with permission.[109] Copyright 2018, The Royal Society of Chemistry.
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with RGD peptides for in vivo active tumor targeting. The 
RGD-decorated aqQDs exhibit highly biospecific properties, 
being highly sensitive and specific for tumor sites.[139]
As luminescent AuNCs show bright fluorescence as well as 
unique plasmon properties, Su et al. designed and synthesized 
fluorescent BSA-encapsulated AuNCs conjugated in a nanogel 
system, followed by tumor targeting peptide iRGD, which 
allowed for tumor targeting drug delivery.[140] Chen et al. estab-
lished a novel nanoplatform of AuNC–cRGD–Apt (aptamer) with 
dual targeting function by conjugation with cyclic RGD (cRGD) 
and Apt AS1411 for tumor targeting, diagnosis, and therapy.[141] 
Liang et al. reported a green and one-step strategy to synthesize 
c(RGDyC)-modified AuNCs (c(RGDyC)–AuNCs) as highly effi-
cient tumor-targeted radiotherapy sensitizers with bright red/
NIR fluorescence and active tumor targeting property.[142]
Beyond that, UCNPs is also combined with RGD for cancer 
targeting and imaging.[143] Cao et al. reported ultrasmall 
sub-5 nm KGdF4 rare earth NPs as nanofluorescent probes for 
in vitro and in vivo tumor targeting imaging by conjugating 
with the RGD peptide, which exhibited up/down-conversion 
luminescence by doped Yb3+/Tm3+ and Eu3+.[144] SWNTs have 
been demonstrated as promising candidates for bioimaging 
and biosensing with unique fluorescence in the NIR region.[145] 
Polo et al. anchored RGD onto SWNTs by confining peptide 
motifs via noncovalent adsorption of single-stranded DNA 
(ssDNA), which is a novel and straightforward approach to 
tune binding affinities of RGD peptide.[146] There are also many 
other FNPs used for RGD connected targeting, such as lumi-
nescent NPs,[147] micelle NPs,[133] and fluorescent liposomes.[148]
In addition to RGD peptides, some other tumor targeting 
peptides have also been studied (Figure 3f–h), such as cell-
penetrating peptide TAT,[149,150] tumor-specific vascular homing 
peptide CGKRK (Cys-Gly-Lys-Arg-Lys),[151] and nucleolin spe-
cifically targeting F3 peptide.[152] TAT peptide is a type of cell-
penetrating peptide, usually decorating to the surface of NPs 
to improve nuclear translocation. Guan et al. developed fluo-
rescent protein NPs based on TAT peptide and enhanced green 
fluorescent protein (EGFP) by gene engineering method. This 
fluorescent protein NPs showed selective tumor accumulation 
suggesting a potential application in tumor imaging and anti-
cancer drug delivery.[150] Liu et al. designed a versatile bioim-
aging probe using highly luminescent cadmium-free CuInSe2/
ZnS core/shell QDs conjugated with CGKRK tumor targeting 
peptides for tumor-targeted multimodal optical imaging.[151]
2.2.3. Antibody-Mediated Targeting
An antibody (Ab), also known as immunoglobulin (Ig), secreted 
by B cells which could bind to the corresponding antigen (Ag) 
specifically and precisely.[153] There are many advantages of Ab, 
such as high specificity, high sensitivity, and easy preparation, 
etc. Therefore, Ab has become the mainstream study of cancer 
targeting application relied on the specific binding of Ag and 
Ab targeting to specific tumor tissues, which could improve the 
therapeutic effect and reduce the side effects. Monoclonal anti-
body (mAb) is a category of Abs produced by identical immune 
cells. In is interesting that mAb has monovalent affinity, which 
means that it can bind to the same epitope of an Ag. Bispecific 
mAb can also be designed to increase the therapeutic targets of 
one single mAb to two epitopes. Therefore, mAb has been con-
sidered as a bullet of the targeted nanocarrier of chemotherapy 
drugs and as powerful tools for manipulating anticancer 
immune responses.[154] With increasingly promising clinical 
results, the discovery and development of therapeutic Abs and 
their derivatives have become a hot topic in recent years.
Human epidermal growth factor receptor 2 (HER2) is the 
homologous gene of neu oncogene (HER2/neu) in rats.[155] This 
receptor signals play an important role in cancer cell prolifera-
tion, differentiation, adhesion, motility, and apoptosis. Hun et al. 
designed a novel kind of polymer fluorescent NPs (PFNPs) modi-
fied with anti-HER2 mAb for detecting ovarian cancer cells with 
fluorescence microscopy imaging technology. The mAb-coupled 
PFNPs can effectively identify the ovarian cancer cells with good 
sensitivity and excellent photostability, providing a new approach 
for diagnosis and therapy of ovarian cancer.[156] Zdobnova et al.[157] 
(Figure 3i) and Balalaeva et al.[158] designed fluorescent nano-
complexes based on QDs and tumor-specific targeting Ab, such 
as anti-HER1 Ab and anti-HER2/neu scFv Ab, that simply com-
bining the targeting and visualization functions in one system. 
Herceptin, the brand name of Trastuzumab, is a humanized mAb 
worked by specific binding to HER2 receptor and slowing down 
cell duplication to target breast cancer cells and treat breast cancer. 
Wang et al. designed a new nanomaterial platform of fluorescent 
BSA-protected AuNCs conjugated with Herceptin (AuNCs-Her) 
for specific targeting to breast cancer cells and tumor tissue as 
a novel fluorescent agent for simultaneous imaging and cancer 
therapy. They found that AuNCs-Her could escape from the endo-
some and carried the Herceptin to the nucleus of breast cancer 
cells to enhance the therapeutic efficacy.[159]
Cetuximab, an anti-EGFR mAb as the EGFR inhibitor, is 
one of the first FDA-approved mAbs for cancer treatment.[160] 
Cho et al. demonstrated the potential application of cetuximab-
conjugated magnetofluorescent silica NPs for the detec-
tion of EGFR-positive colon cancer using in vivo imaging 
approaches.[161] Deepagan et al. prepared MFNPs based on QDs 
and drug inside the PLGA matrix and conjugated cetuximab for 
targeting EGFR overexpressed cancer cells (Figure 3j).[162] Yang 
et al. used a single-chain anti-EGFR Ab (ScFvEGFR) as targeting 
molecule conjugated to the surface of QDs, specifically binding 
to EGFR overexpressed on cancer cells with a fluorescent signal 
for optical imaging.[163] Carcinoembryonic antigen (CEA) is 
a set of glycoproteins highly related to cell adhesion, which 
are normally produced during fetal development but stopped 
before birth.[164] Consequently, the CEA level is usually very low 
in healthy adults’ blood but increased in some types of cancer, 
which means that it can be used as a tumor target in cancer tar-
geting therapy. Tiernan et al.[165] reported fluorescent dye-doped 
silica NPs and rare earth doped UCNPs conjugated with tar-
geted anti-CEA Ab for cancer targeting imaging and therapy. Li 
et al.[166] reported a soft nanomaterial-based targeting polymer-
somes with NIR dyes and Abs (anti-CEA Ab and anti-EGFR Ab). 
Recently, Wang et al. synthesized Ab-UCNPs conjugates based 
on core–shell NPs UCNPs@SiO2 linked to rabbit anti-CEA8 
Ab, which could specific attach to the surface of HeLa cells 
(Figure 3k).[167] Additionally, some other Abs are also used to 
combine with FNPs for targeting cancer and therapy. Wu et al. 
used poly lactic-co-glycolic acid NPs (PLGA NPs) conjugated 
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with MUC1 Ab as a nanocarrier for specific targeting delivery 
of paclitaxel into human pancreatic ductal adenocarcinoma 
cells in vitro and in vivo and loaded with FI agents for visual 
imaging.[168] Zheng et al. designed an ICG-containing nano-
structure (ICG–PL–PEG) conjugated with integrin αvβ3 mAb 
leading to selective internalization and retention in target tumor 
cells. ICG–PL–PEG has both fluorescent marker and imaging-
guided photothermal therapy capabilities, showing great poten-
tial for clinical applications.[169]
2.2.4. Aptamer-Mediated Targeting
Nucleic acid Apt is a single-chain oligonucleotide with 20–60 
bases screened by systematic evolution of ligands by exponen-
tial enrichment (SELEX) with functions of high affinity and spe-
cific binding, which were first screened out by Ellington[170] in 
1990. By virtue of its inherent nature of high specificity and high 
affinity, Apt has been widely studied by researchers for diagnosis 
and treatment of many diseases, especially for tumor-targeted 
therapy. Compared to Ab, nucleic acid aptamers have many 
unique advantages, such as small molecular weight, artificial 
synthesis, high stability, and low immunogenicity, suggesting 
that nucleic acid Apt is an ideal tool for cancer-targeted therapy. 
In recent years, researchers have constructed a variety of Apt–
FNPs complexes for specific targeting imaging and recognition 
of cancer cells. For, e.g., chitosan NPs–Apt,[171] Pt-PLGA–PEG 
NPs-Apt,[172] tryptophan–phenylalanine dipeptide NPs (DNPs) 
(Figure 3m),[173] MnO2 nanosheet–Apt,[174] rGO nanosheets–
Apt,[175] AgNCs–Apt,[176,177] etc. Dhar et al. have reported a unique 
strategy using PLGA–b–PEG NPs functionalized with PSMA 
targeting Apt on the surface as a vehicle for targeted delivery of 
platinum (IV) to prostate cancer cells (Figure 3l).[172] Using Apt 
technology, Tallury et al. synthesized fluorescent chitosan NPs, 
which were specifically targeted to human leukemia cells.[171] 
According to many studies, DNA Apt can specifically bind Mucin 
1 (MUC1) which can target NPs to a cancer cell of interest.[178] 
Fan et al. designed DNPs based on dipeptide to shift the peptide’s 
intrinsic fluorescence from the ultraviolet to the visible range as 
imaging probes. And then the DNPs were further functionalized 
with MUC1 Apt and doxorubicin for targeting cancer cells and 
monitoring drug release by real time fluorescent image.[173]
Active targeting is a very important consideration when 
designing an antitumor drug delivery nanocarrier. It deter-
mines the actual drug delivery effect and the bioavailability of 
the drug. Active targeting therapeutic strategies are expected 
to target tumor tissues more specifically than just EPR effect. 
The increased effectiveness of active targeting nanoparticles is 
due to the improved targeted cell recognition and targeted cell 
uptake rather than better tumor accumulation.[41,179] However, 
an emerging field of nanotoxicology has concerns regarding 
whether NPs could pose a threat to both the environment and 
human health with side effects which need more study.[180]
2.3. The Tumor Microenvironment
TME, i.e., the internal environment where tumor cells are gen-
erated and reside, including not only the tumor cells themselves, 
but also the surrounding multiple cells, such as fibroblasts, adipo-
cytes, immune and inflammatory cells, glial cells and other cells, 
as well as the intercellular substance, microvessels and the bio-
logical molecules infiltrated in the ECM.[181] It has become evident 
the need of seeking a new and alternative targeting strategy, TME, 
for cancer treatment as it plays an important role in development, 
progression, and metastasis of a tumor and in the development of 
drug resistance.[52] There are many differences in physicochemical 
properties between TME and normal internal environments of the 
human body, such as low oxygen, low pH, and high pressure.[182] 
More than 100 years ago, Paget first postulated the important 
role played by microenvironment in metastasis formation and 
proposed the famous concept of “seed and soil” based on clinical 
observation of organ-specific metastasis of breast cancer.[183] How-
ever, this hypothesis did not receive enough attention at that time, 
and the treatment idea was limited to the tumor cells themselves, 
which lead to an extremely difficult battle against cancer. Until 
recently, more and more scientists began to realize that tumor 
and TME are an integral whole (Figure 5). Therapeutic strategies 
of targeting to TME have their own advantages, such as tumor 
stromal cells having genetic stability with less mutation and resist-
ance. The heterogeneity of the TME is smaller than that of tumor 
cells, and the therapeutic effect is more stable. Studies found that 
nanomedicines can accumulate in the tumor site through the 
EPR effect, but most of them are only retained in the perivascular 
areas with limited ability to penetrate into tumor cells due to the 
dense interstitial matrix.[184] Dong et al. presented mesoporous 
silica nanoparticles (MSN) loaded with a chemotherapeutic agent, 
DOX, as well as a NO donor (S-nitrosothiol) to create DN@MSN, 
which could active MMP to degrade collagen in the tumor extra-
cellular matrix. According to their results, DN@MSN enhanced 
the EPR effect of NPs and improved the tumor penetration of 
both the nanovehicle and cargo (DOX), leading to significantly 
improved antitumor efficacy.[185] Therefore, it is necessary to study 
the TME from both biological and philosophical perspectives.
2.3.1. Physiological Environment
As mentioned above, the TME is quite different from normal 
human internal environments in terms of physical and 
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of tumor cells, stroma cells, and external physiological environment.
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chemical properties, and its characteristics of low oxygen, low 
pH, and high pressure are quite remarkable, resulting in many 
growth factors, such as cytokines and various immune inflam-
matory reactions produced by proteolytic enzymes, which are 
very conducive to tumor proliferation, invasion, adhesion, angi-
ogenesis and promote the generation of malignant tumors.[186]
Hypoxia: Thomlinson and Grey became aware of the hypoxia 
in many malignant tumors in 1955.[187] Necrosis often occurs 
in anoxic regions, which is more prone to tumor proliferation 
and metastasis. Many studies around the world have found that 
hypoxia-inducible factor-1α (HIF-1α) can be highly expressed 
in hypoxic tumor tissues,[188] which plays an important role 
in tumor development and metastasis, making it became an 
important antitumor target.[189] Kiyose et al. developed hypoxia-
responsive near-infrared fluorescent probes conjugating a black 
hole quencher (BHQ-3) as a hypoxia-responsive moiety for FI of 
hypoxic cancer cells and real-time monitoring of ischemia.[190] 
Since a BHQ-3 with an azo-linkage quenched the NIR emis-
sions, the probes were nonfluorescent under normoxic con-
ditions, while under hypoxic conditions, the azo-linkage was 
reduced and the fluorescence was mostly recovered. Simi-
larly, Piao et al. and Cai et al. developed fluorescent probes 
to detect different levels of hypoxia.[191] Although many fluo-
rescent probes have shown promising results in vitro, the in 
vivo application has been limited because of nonselectivity and 
instability of fluorescent probes under physiological conditions. 
Therefore, it is necessary to develop novel nanocarriers, such as 
FNPs, for hypoxic cancer targeting. Recently, various FNPs have 
been developed for targeted cancer imaging.[192] Bartholomeusz 
et al. described a new approach for delivering small interfering 
RNA (siRNA) into cancer cells by noncovalently binding siRNA 
with SWCNTs targeted to hypoxia-HIF-1α which strong specific 
inhibit the cellular HIF-1α activity implied that SWCNT/siRNA 
complexes have the promising value as therapeutic agents.[193] 
Perche et al. first reported the specific nanocarrier based on 
hypoxia-induced siRNA uptake and silencing as well as azoben-
zene imparts hypoxia for cancer targeting. They found that 
hypoxia-activated green fluorescent protein (GFP) is silence in 
vitro and downregulate in vivo in GFP-expressing tumors after 
intravenous administration which means that this designed 
nanocarrier represents a tumor-environment-responsive 
modality for tumor targeting.[194]
Low pH: Hypoxia can induce intracellular glycolysis, leading 
to a drop in pH. However, experiments have shown that even in 
the situation of low lactate or artificially increased tumor tissue 
oxygen pressure or blood supply, low pH still exists. Regard-
less of the cause, the extracellular microenvironment is acidic 
(pH 6.5–6.9), and the cancer cells themselves remain neutral 
(pH 7.2–7.4). Chen et al. designed and synthesized pH-trig-
gered probes based on the encapsulation of the 19F contrast 
agent in AuNP-capped fluorescein-functionalized mesoporous 
silica NPs (FMSNs), called Au–FMSNs, for the intracellular 
MRI and FI.[195] Zhou et al. have reported some tunable, pH-
activatable micellar (pHAM) NPs with pH-sensitive dye, which 
could render a fast and ultrasensitive response to changes in 
pH value.[196] Zhao et al. designed an oligopeptide self-assembly 
fluorescent nanostructure, which can be triggered from self-
assembled stage to dissociated stage when encountering a 
subtle pH-changed TME.[197]
2.3.2. Tumor Stroma Cells
At present, it is increasingly recognized that tumor stroma con-
tains different cell types, including tumor-associated fibroblasts 
(TAFs), tumor-associated macrophages (TAMs), and neovascu-
larization cells, and so on, which play different and important 
roles in promoting the formation of tumor invasion and metas-
tasis and serve as the soil for tumor growth. Each cell type plays 
different roles and has their own different functions.
Tumor-Associated Fibroblasts (TAFs): TAFs are the main 
member of tumor stroma cells with the function of secreting 
extracellular matrix components, growth factors, cytokines, 
and hormones, which can promote tumor initiation, progres-
sion, and metastasis.[198] Miao et al. argues that NPs might be 
exploited to target the expression of secreted cytotoxic proteins 
from TAF as a new anticancer strategy. In order to prove their 
idea, lipid-coated protamine DNA complexes (LPD NPs) were 
loaded with TNF-related factor sTRAIL which triggered apop-
tosis in a wide range of tumor cells and incorporated with DiI 
fluorescent probe. According to their result, TAF could be used 
as sTRAIL producing cells that triggered apoptosis in tumor 
cell nests, which offered an effective strategy to treat desmo-
plastic cancers and further suppressed tumor growth.[199]
Myeloid-Derived Suppressor Cells and Tumor-Associated Mac-
rophages: MDSCs are a heterogeneous group of cells derived 
from bone marrow. It can significantly inhibit immune 
responses and regulate wound repair and inflammation, which 
is rapidly amplified in cancer.[200] TAMs are a central compo-
nent in the close association between chronic inflammation and 
cancer since they are recruited to tumor tissues as a response 
to cancer-associated inflammation and play an important role in 
the TME.[201] TAMs are the major immunoregulatory cells to the 
immune response located in the stroma of solid tumor in the 
tumor progression (e.g., cancer cell proliferation, metastasis, and 
invasion) or in the antitumor processes. In malignant tumors, 
TAMs are closely related to the progression and metastatic inva-
sion of tumors, which can provide inflammatory cytokines and 
growth factors for tumor cell survival.[202] Hence, MDSCs and 
TAMs are expected to be a potential target for cancer treatments. 
Kourtis et al. examined the cell-level biodistribution kinetics 
after administering ultrasmall pluronic-stabilized poly (pro-
pylene sulfide) NPs labeled with Dy649-maleimide (NPs-Dy649) 
in the mouse.[203] They found that these NPs have especially 
strong targeting to myeloid cells when administered intrader-
mally (i.d.). In particular, MDSCs were efficiently and preferen-
tially targeted in tumor-bearing mice, meaning that the NPs can 
be potentially useful for reversing the highly suppressive activity 
of these cells in the tumor stroma. Miller et al. designed the 
therapeutic NPs comprising a fluorescent platinum (IV) prodrug 
and a clinically tested polymer platform (PLGA–b–PEG) for the 
first time allow simultaneous imaging. They found that thera-
peutic NPs accumulated at high levels within TAMs served as 
cellular drug reservoirs. TAMs release the Pt payload into neigh-
boring tumor cells over time.[204] Cuccarese et al. used optical 
tissue clearing and a TAM-targeting injectable FNPs to examine 
3D TAMs composition and nanoparticle-based drug delivery in 
murine pulmonary carcinoma, which offered a creative method 
for rapid tumor volume assessment and spatial information on 
TAMs infiltration at the cellular level in entire lungs.[205]
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2.3.3. Extracellular Matrix
The ECM is a 3D network of extracellular macromolecules, such 
as collagen, enzymes, and glycoproteins, that provide structural 
and biochemical support to surrounding tumor cells and stromal 
cells. As many fibroblasts are transformed into CAFs during car-
cinogenesis, ECM production decreases, and malformed ECM 
is produced. In addition, CAFs produce matrix metalloprotein-
ases (MMP) that cleave the proteins within the ECM, which 
may allow cancer cells to escape from their in situ location and 
metastasize to the whole body. Furthermore, dense and stiff 
ECM in solid tumor tissues can inhibit deep penetration of NPs 
drug carriers and decreases their therapeutic efficacy. So, Lee 
et al. suggest the ECM remodeling strategy for enhanced tumor 
targeting of Cy5.5-labeled glycol chitosan NPs.[206]
2.4. Multiple Targeting Strategies
FNPs combined with passive or active tumor targeting or other 
targeting strategies are promising for cancer diagnosis and 
therapy. However, suboptimal targeting effect of most targeting 
strategies, drug leakage during blood circulation, low tumor 
tissue accumulation/retention, and cellular internalization 
leads to unsatisfactory treatment outcome. To address these 
problems, the designed fluorescent targeting NPs (FTNPs) 
are expected to have multitargeting functions facing different 
environments. Multiple targeting, a novel targeting strategy 
that consists of two or more targeting stages including tumor 
tissue targeting based on EPR effect, tumor cell targeting based 
on targeting ligands and TME-based targeting and other strate-
gies, shows great potential to enhance tumor therapeutic effect 
(Figure 6).
The multiple targeting nanoplatforms are generally based on 
the EPR effect combined with other strategies such as ligand-
based active targeting, TME-based targeting, which are expected 
to show high stability in blood and enhance tumor retention, 
cellular internalization, and even nuclear uptake.
2.4.1. EPR Effect and Active Targeting
As shown in Figure 6, for the EPR effect combined with active 
targeting, there are several parts as reviewed. First, FA was 
used to improve the targeting efficiency of the EPR effect. 
Cui et al. developed a multifunctional nanostructure consisting 
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Figure 6. Integration graph of multiple targeting strategies. EPR and active targeting: FASOC–UCNP. Reproduced with permission.[207] Copyright 2013, 
American Chemical Society. UCNP@Fe–MIL-101_NH2. Reproduced with permission.[208] Copyright 2015, Wiley-VCH. Multifunctional Micellar. Repro-
duced with permission.[149] Copyright 2011, American Chemical Society. RGD–QD–MoS2 NSs. Reproduced with permission.[211] Copyright 2017, RSC. 
InP QDs–VEGFR2 antibody. Reproduced with permission.[213] Copyright 2017, American Chemical Society. DOC/AS1411/Cy5.5. Reproduced with per-
mission.[215] Copyright 2017, American Chemical Society. EPR & TME: Ce6–PEG–Azo–PCL. Reproduced with permission.[216] Copyright 2018, American 
Chemical Society. P1@P2. Reproduced with permission.[220] Copyright 2017, American Chemical Society. Active targeting & TME: iPAPD. Reproduced 
with permission.[228] Copyright 2017, American Chemical Society. EPR effect &Active targeting &TME: cRGD–UPSi. Reproduced with permission.[227] 
Copyright 2019, Springer Nature.
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of UCNPs and photosensitizer zinc (II) phthalocyanine (ZnPc) 
for PDT. The folate-modified amphiphilic chitosan (FASOC) 
was coated on the surface of UCNPs for active targeting and 
ZnPc anchoring close to the UCNPs. The overall size of the 
ZnPc-loaded FASOC–UCNPs was ≈50 nm in diameter, which 
led to accumulation in tumor tissues through the EPR effect 
and enhanced targeting to tumor by FA-based active ligand.[207] 
Li et al. have designed octahedral core–shell nanostructures 
named UCNPs@Fe-MIL-101-NH2 modified with FA (UMP-FA) 
resulting in tumor targeted dual-mode imaging of upconver-
sion luminescence (UCL) imaging and MRI. According to their 
result, there is a weak accumulation of UCNPs due to the EPR 
effect, while UMP-FA is successfully and efficiently delivered 
to tumors because of the receptor binding.[208] Additionally, Fan 
et al. used H-ferritin (HFn) nanocarrier for crossing the blood 
brain barrier (BBB) and specifically targeting and entering 
glioma cells to kill them through both passive targeting (EPR 
effect) and active targeting specific bound to HFn receptor over-
expressed in glioma.[209]
Second, NPs were modified with RGD peptide to improve 
the targeting efficiency based on the EPR effect. Haedicke 
et al. used multifunctioned calcium phosphate NPs as carrier 
conjugating with i) Temoporfin as a photosensitizer, ii) the 
RGDfK peptide for tumor targeting, and iii) the fluorescent dye 
molecule DY682–NHS for near-infrared fluorescence (NIRF) 
optical imaging in vivo.[210] Here, NP–DY682 showed just a 
short tumor accumulation and a fast elimination thereafter, 
suggesting an enrichment due to the EPR effect, while the 
RGD-conjugated NPs showed an enhanced specific accumula-
tion at 24 h after injection. Xiong and Lavasanifar developed a 
polymeric micelles system that integrates multiple functions 
including near-infrared FI, dual targeting to cancer by the RGD 
peptides, and the TAT peptide for cancer targeted codelivery of 
siRNA and doxorubicin.[149] Characterization studies provided 
evidence of the micelles with an appropriate size for tumor tar-
geting by the EPR effect (≈100 nm), while the RGD allows for 
enhanced recognition and uptake of the nanocarrier by cancer 
cells. Zhang et al. have successfully prepared RGD–QD–MoS2 
nanosheets (NSs) with excellent fluorescence, photothermal 
conversion, and cancer-targeting properties by functionalizing 
single-layer MoS2 NSs with fluorescent QDs and RGD pep-
tides.[211] In addition, Mei et al. used two targeting ligands, 
angiopep-2 and activatable cell penetrating peptide (ACP) 
to modify NPs for tumor targeting delivery. As a result, NPs 
could significantly distribute into tumors through EPR while 
targeting ligands could improve the targeting ability of NPs.[212]
Third, antibodies and aptamers are also used to modify NPs 
to improve the targeting efficiency based on the EPR effect. Wu 
et al. modified near-infrared fluorescent QDs (InP QDs) with 
a vascular endothelial growth factor receptor 2 (VEGFR2) mAb 
for targeted drug delivery. The VEGFR2 Abs effectively bound 
to InP QDs to target tumor angiogenesis. In this design, the 
InP QDs-VEGFR2 can be delivered to tumor cells by both pas-
sive and active targeting modes.[213] Kwon et al. conjugated 
anti-MUC1 Abs, aberrantly overexpressed in breast cancer, and 
TCP1 peptides, a vasculature-targeting peptide for colorectal 
cancer, to multifunctional silica-based nanocapsules (SNCs) 
that encapsulated two distinct upconversion chromophore 
pairs with functions of selectively targeting cancer cells and 
FI for early diagnosis of tumor malignancy. Both in vitro and 
in vivo experimental results showed greater accumulation of 
nanocapsules at tumor sites than the EPR effect, which still 
allowed accumulation at the tumor site in the absence of tar-
geting moiety because of tumor vascular malformation.[214] 
Wang et al. designed self-assembled multifunctional dioleoyl 
clofarabine (DOC) NPs as tumor-targeted drug delivery com-
bined with Apt AS1411 and Cy5.5-labeled fluorescent DNA via 
molecular recognition between the clofarabine and the thymine 
on DNA for cancer targeting and FI. From their result, the fluo-
rescence signal of DOC/Cy5.5 NPs at the tumor site increased, 
which could be attributed to the EPR effect. In contrast, DOC/
AS1411/Cy5.5 NPs could accumulate at the tumor site more 
effectively when loaded with AS1411, indicating that the Apt 
indeed enhanced the targeting capability to tumor.[215]
2.4.2. EPR Effect and TME
Using EPR combined with TME, mainly hypoxia[216] and low 
pH,[217–221] several strategies have been designed for cancer 
therapy. In the study of the Cheng’s group, a supramolecular 
drug delivery system was constructed based on fluorescent 
star polycation P1 and charge-reversal anionic copolymer P2, 
obtaining P1@P2 which was stable in blood and accumu-
lated in tumor through the EPR effect and responded to the 
tumor extracellular and intracellular microenvironment for 
programmed cellular uptake and drug release.[219] Wang et al. 
developed a pH/H2O2 responsive Si QD-based nanocomplexes, 
which could target the tumor site by the EPR effect and TME 
response.[220] The combined strategy of EPR effect and TME 
improved the low targeting efficiency of EPR.
2.4.3. Active Targeting and TME
Recently, scientists used different ligand-modified FNPs to 
design microenvironment-responsive nanocarriers, such as FA-
conjugated pH-sensitive hollow ZnO,[222] pH-triggered Au-fluo-
rescent mesoporous silica NPs,[195] HA-conjugated fluorescent 
carbon NPs,[223] mesoporous silica NPs,[224] and RGD-modified 
carbon dots,[225] TAT-modified polymeric micelle,[226] and so on. 
Wang et al. selected two established TME signals, namely angi-
ogenic tumor vasculature and low extracellular pH as targets 
as design basis. They established a series of ultra pH-sensitive 
(UPS) nanoprobes composed of ultra pH-sensitive core for pH 
response, a series of fluorophores for multicolored imaging and 
a RGD targeting unit that combined active targeting and pH 
response.[227] An acid-responsive diblock copolymer combined 
with an iRGD-modified polymeric prodrug of doxorubicin 
(DOX) termed as iPAPD, which could specifically accumulate 
at the tumor site through EPR effect, followed by pH-triggered 
cellular uptake within the tumoral acidic microenvironment.[228]
2.4.4. EPR Effect and Active Targeting and TME
In order to further improve the efficiency, FA-functionalized 
amphiphilic alternating copolymer poly (styrene-alt-maleic 
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anhydride) (FA–DABA–SMA) are designed for targeted drug 
delivery, which has three levels of control including the EPR 
effect, FA-based active targeting, and pH responsiveness in the 
cancer microenvironment simultaneously, showing a prom-
ising new active tumor targeting drug delivery system.[229] 
The nanoparticle modified with EGFP–EGF1, which can bind 
well to A549 tumor cells and other stromal cells including 
neovascular cells, TAFs and TAMs, etc., and also accumulate at 
tumor site because of the EPR effect.[230] Based on the acidic, 
angiogenic TME, the combined design strategy are tried. Ultra 
pH-sensitive fluorescent nanoprobe containing ultra pH-sensi-
tive core, fluorophores and targeting unit are designed, which 
is robust and universal used in 10 different tumor models’ 
detection.[227]
2.5. Cell Membrane Permeability Targeting Mechanism
At present, the main three mechanisms for designing nano-
materials improved the tumor targeting of the drugs, lower 
the side effects to normal tissues. However, the low targeting 
performance and the failure in the clinically application push 
the scientists in the targeting nanomedicine design field eager 
to find the new mechanism and strategies to develop the spe-
cific tumor targeting. Just recently, Wang and co-workers found 
a new graphene-based tumor cell nuclear targeting fluorescent 
nanoprobe (GTTN) shown in Figure 7.[37] GTTN is a graphene-
based amphiphilic fluorescent probe modified by sulfonic acid 
and hydroxyl groups. GTTN has an excellent fluorescence sta-
bility (Figure 7b) and ultrasmall size (3.35 ± 0.15 nm on average) 
with amphipathicity, which is very stable in the blood circula-
tion. It does not combine with blood cells, hemoglobin, etc., 
and maintains its physical and chemical properties well in vivo. 
This probe has the characteristic of specific tumor nuclear tar-
geting of tumor tissue in vivo but does not enter normal tissue 
cells (Figure 7c–e). GTTN recognizes tumor cells and normal 
cells through the differences of cell membrane’s permeability 
(Figure 7a). Wang et al. named this new targeting mechanism 
as the cell membrane permeability targeting (CMPT) mecha-
nism. Small size, amphiphilic structure, electronegativity of 
GTTN and their ability to keep their properties not altered 
by protein corona are important determinants for targeting 
to tumor nuclei. Deeper researches are needed to use CMPT 
mechanism to design different NPs/nanomedicines with great 
tumor targeting performance. GTTN can distinguish the inter-
face between tumor tissue and normal tissue (Figure 7j) and 
recognize tumor tissue in a very early stage and track the inva-
sion and metastasis of tumor cells at the single cell level. More 
importantly, the tumor targeting rate through GTTN can be 
as high as 50% (Figure 7f–i). Wang et al. used two methods to 
express the tumor targeting rate. One is using the fluorescent 
intensity of the tumor divided by the total fluorescent inten-
sity of tumor. The other is the GTTN concentration in terms 
of the percentage of the injected dose (ID%). The results of 
both methods showed that the highest targeting rate was about 
50% at the tumor site, which is much higher than that of NPs/
nanomedicines designed with the EPR effect (<5%). According 
to Chan and co-workers after surveying the literature from the 
past 10 years, only 0.7% (median) of the administered NPs dose 
is found to be delivered to a solid tumor.[231] At present, after 
some efforts, (mainly the modification of nanomaterials them-
selves), some nanomaterials have improved the tumor targeting 
rate. Yu et al. designed a DNA/UCNPs nanocomposite to pre-
cisely target to tumor site through preprotect the FA by longer 
DNA, which could be triggered by the acidic TME. Through 
this strategy, the targeting effect of UCNPs@PAA–DNA1/2 on 
tumors was 12.1 ± 0.7% ID g–1.[109] The targeting ratio of in vivo 
assembly NIR-II downconversion NPs (DCNPs) modified with 
complementary DNA (L1 or L2) and targeting peptides (follicle-
stimulating hormone, FSHβ) for distinguishing tumor tissue 
from normal tissues were found to be of ≈17.5% ID g–1.[232] The 
calculation methods of targeting ratio are different make the tar-
geting ratio is more complex and difficult to compare.[37] As we 
mentioned earlier (part 2.1.5), even if the nanomaterials reach 
to the tumor tissue, it is difficult to actually enter into the tumor 
tissue. Therefore, the dose that actually enters into the tumor 
cell is much lower. GTTN targets to the tumor tissue cell nuclei 
directly with high targeting ratio. In addition, GTTN has good 
biocompatibility and low toxicity. It is metabolized very fast in 
vivo and can be metabolized completely after 48 h without accu-
mulating in normal organs and producing long-term toxicity. 
Following this brand-new CMPT mechanism design principle, 
the NPs/nanomedicines can accurately target to the tumor cell 
nucleus in vivo with minimum uptake by normal tissues. With 
the development of material science and synthetic biology sci-
ence, precisely engineering the NPs/nanomedicines according 
to the design principle is a complete reality. We are sharing a 
bright future for tumor therapy with CMPT.
3. Biodistribution, Clearance Pathways,  
and Biosafety of FNPs
Although targeted NPs have great potential in the diagnosis 
and therapy of cancer, their actual and potential toxicity are 
still a concern and are the major obstacle of clinical applica-
tion.[233] Successful translation of the FNPs from laboratories 
to clinics requires exhaustive and elaborate studies involving 
the biodistribution, clearance pathways, and biosafety for in 
vivo biomedical imaging applications. The United States FDA 
requires that agents injected into human body, especially diag-
nostic drugs, must be completely eliminated within a reason-
able period of time.[234] While the FTNPs designed as different 
modalities exhibit diversity in chemical structures, properties, 
and functionalities. They often share some similar distribution 
and clearing behaviors in vivo. However, FTNPs are often rap-
idly sequestered from the blood, then are caught and devoured 
by RES organs (liver, spleen, and so on). Excretion is an impor-
tant biological process that prevents injury and toxicity by 
removing unwanted substances from the body.[51]
Kumar et al. synthesized organically modified silica 
(ORMOSIL) nanoparticles, conjugated with NIR fluorophores 
and 124I for FI and PET imaging. Biodistribution studies 
showed that the ORMOSIL NPs accumulated more in liver, 
spleen, and stomach than in kidney, heart, and lungs. The clear-
ance studies indicated hepatobiliary excretion of the nanoparti-
cles. Histological analysis confirmed that the ORMOSIL NPs 
did not lead to any adverse effect or any other abnormalities in 
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the tissues.[235] Zhou et al. reported that the glutathione-coated 
luminescent gold NPs (GS-AuNPs) were cleared through renal 
with more than 50% of the GS-AuNPs were found in urine 
within 24 h after injection. Only (3.7 ± 1.9) % of the GS-AuNPs 
were accumulated in the liver with minimized nanotoxicity.[236] 
Lu et al. found that fluorescent mesoporous silica nanoparti-
cles (FMSNs) preferentially accumulate in tumors and the next 
strongest accumulation was found in liver and kidney. For bio-
compatibility experiments, there was very low toxicity observed 
in vivo.[237] Tao and co-workers found that C-dots mainly accu-
mulated in the RES organs, such as liver and spleen, after 
intravenous injection. This in vivo behavior is similar to many 
other nanomaterials for bioapplication.[238] There are two main 
excretory pathways: the renal (urine) and hepatic (bile to feces) 
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Figure 7. The mechanism of CMPT and the tumor cells nuclear targeting properties of GTTN. a) Schematic diagram of CMPT; b) High fluorescence 
stability of GTTN without quenching under 405 nm laser continuous irradiation for 40 min. The above row (GTTN), the bottom row (DAPI); c) In 
vivo fluorescence images of tumor-bearing mice after the intravenous injection of 100 mg kg–1 GTTN for 0.5, 1, 2, 8, and 24 h; d,e) Confocal images 
of frozen sections of tumor and normal tissues after the intravenous injection of GTTN for 0.5 h. Scale bar, 20 µm. d) Subcutaneous tumor cells and 
human hepatoma tumor. e) Normal cells; f,g) Average signals of GTTN from isolated organs of ex vivo images after GTTN injection (100 mg kg–1) 
for 0, 0.5, 1, 2, 8, and 24 h. Mean ± SEM; n = 5 per group. f) Subcutaneous tumor model. g) Orthotopic tumor model; h,i) The tumor targeting rate 
after the intravenous injection of GTTN for different times. h) Subcutaneous tumor model. i) Orthotopic tumor model; j) Confocal images of tumor 
interfacial resolution. T: tumor tissue. P: pericarcinomatous tissue. N: normal tissue. Scale bar, 30 µm. a–j) Reproduced with permission.[37] Copyright 
2019, Wiley-VCH.
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pathways of FTNPs. According to our statistics, renal excre-
tion is the main way of most of FTNPs cleared from the body, 
such as gold NPs,[239–242] UCNPs,[243–245] and FCNMs[227,246–249] 
(Table 1). Only a little FNPs are eliminated through hepatic, 
such as Ag2S QDs,[250] CdSe0.25Te0.75/CdS,[251] and so on.
4. Applications in Cancer Management
FTNPs offer a useful platform for exploring the challenges 
in the field of nanomedicine, diagnosis, and cancer therapy. 
FNPs have been widely utilized in the development of high-
performance biosensors to take advantage of their favorable 
biocompatibility, surface tailoring-ability, fast response, and 
good reproducibility.[252] These advantages play a major role in 
tumor imaging and diagnosis, nanofluorescent biosensor, drug 
delivery, and surgical treatment.
4.1. FI-Based Cancer Diagnosis
In Table 2, the main medical-imaging modalities used in 
clinical practice today were summarized. The aforementioned 
tomographic imaging modalities that rely on deep-penetrating 
radiation can achieve infinite penetration depth but have major 
limitations including adverse effects to hazardous ionizing 
radiation (CT and PET), intrinsically limited spatial resolutions 
(MRI and PET), poor temporal resolution, lack of exogenous 
and endogenous probes, and non-real-time dynamic visuali-
zation due to the long collection time.[7,250,253] In contrast, in 
vivo FI does not suffer from these drawbacks like tomographic 
imaging modalities, providing the benefits of real-time imaging 
acquisition and diffraction-limited, spatial resolution in living 
organisms, and nonhazardous optical radiation of fluorescent 
probes, which has emerged as a promising tool for improving 
tumor diagnosis, monitoring therapy response and detecting 
residual tumor lesions.[254] Despite the many advantages, in 
vivo FI has poor photon penetration depth in most mammalian 
tissues which are usually opaque to light in the visible spec-
trum (400–700 nm in wavelength) coupled with interference 
from the tissue autofluorescence.[255] Therefore, it is essential to 
seek the deep-tissue and real-time FI probes such as NIR-I and 
NIR-II fluorophores or FNPs and develop new imaging instru-
mentation. In this section, we focus on the recent advances of 
FTNPs applied for biomedical imaging.
Fluorescence-based optical imaging technology provides an 
effective and promising way for safe, noninvasive, and real-time 
detection with the key advantages of real-time synchroniza-
tion, high resolution, and specific targeting performance based 
on passive targeting or active targeting or both.[256] Recently, 
FTNPs have been deeply studied because of their visual tar-
geting imaging and recognition between tumor tissue and 
normal tissue for tumor early diagnosis and accurate surgical 
excision (Figure 8). Such as shown in Figure 8a, Robinson et al. 
functionalized the SWNTs with a novel polymer, prolonged 
the blood circulation, and improved the EPR effect.[257]  
Liu et al. reported a kind of GS-coated AuNPs with diameters 
of ≈2.5 nm. They compared in vivo passive tumor targeting by 
GS–AuNPs and IRDye 800CW.[239] (Figure 8b) They found that 
GS–AuNPs behave like the IRDye 800CW in the initial stage 
of tumor targeting, but the tumor retention time of the GS–
AuNPs is much longer than the dye molecules, indicating that 
the GS–AuNPs retain the EPR effect while achieving efficient 
renal clearance. As shown in Figure 8a,c,d, researchers modi-
fied the NPs with PEG that improved the circulation time and 
enhanced the EPR effect because of the unique physiochem-
ical property and excellent biocompatibility of PEG.[240,250,257] 
Figure 8e–g shows the active targeting based on RGD and FA 
applied for precise tumor-targeted FI.[109,232,258] Especially, Wang 
et al. modified the DCNPs with DNA and RGD that could be 
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Table 1. The clearance pathways of FTNPs.
Core structure Surface Size [nm] Targeting strategy Clearance pathway In vivo toxicity Refs.
Ag2S QDs DHLA/six-armed PEG 5.4 EPR Hepatic Minimal toxicity [250]
CdSe0.25Te0.75/CdS MUA 7 EPR Hepatic Nontoxicity [251]
Gold NPs Glutathione 2.5 EPR Renal – [239]
Gold NPs PEG 2.3 EPR Renal – [240]
Gold NCs Glutathione 2 EPR & active Renal Nontoxicity [241]
Gold nanocages Red blood cell 
membranes
89.05 EPR Renal Nontoxicity [242]
NaGdF4:Yb NPs PEG2000 2.1 EPR & active Renal – [243]
Ultrasmall Pd nanosheets Glutathione 4.4 EPR Renal Nontoxicity [310]
UCNPs(153Sm) PEG 8 EPR Renal – [244]
Ba2GdF7 NPs Targeted peptide 6.5 EPR&active Renal Minimal toxicity [245]
Carbon dots NIR dye ZW800 3 EPR Renal – [246]
Gd–graphene carbon NPs – 5 EPR Renal Nontoxicity [247]
Gd–carbon dots – 12 EPR Renal – [248]
C60-based NPs RGD 106 Active Renal Minimal toxicity [249]
GTTN – 3.5 CMPT Renal Nontoxicity [37]
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applied for metastatic ovarian cancer resection through image-
guided surgery.[232] Qi et al. introduced smart NPs combined 
PAI, FI, and PDT based on active tumor-targeting with YSA 
(YSAYPDSVPMMS) peptide as well as the passive tumor-
targeting EPR effect[259] (Figure 8h).
Fluorescence-targeted imaging used FTNPs for the real-time 
and in situ detection of the tumors by monitoring the fluores-
cence phenomenon.[260] FTNPs have shown good prospects in 
the field of tumor diagnosis, such as FL dye-doped NPs,[165,261,262] 
QDs,[158,263] MNCs,[176,264] UCNPs,[265–267] FCNMs,[24,218,268] and 
semiconductor polymer NPs (SPNPs).[269,270]
ICG is the only NIR dye that is FDA approved for clinical 
use and pharmaceutical applications. So, FL dye-doped NPs 
are becoming more and more widely used in the diagnosis of 
cancer. FI of colorectal cancer cells can improve tumor locali-
zation, allow intraoperative staging, facilitate surgical resec-
tion, and thus improve the prognosis of patients. Both Tivony 
et al.[261] and Tiernan et al.[165] used fluorescent dye and anti-
CEA Ab to modify NPs for medical targeting imaging of colo-
rectal tumors in vitro and in vivo. Tiernan et al. demonstrated 
live, specific, in vivo imaging of colorectal cancer cells using 
Ab-targeted FNPs for the first time. In order to noninvasively 
observe the heterogen distribution of these abnormal indicators 
in vivo and further reveal their common behaviors, Ma et al. 
constructed a protease-triggered fluorescent probe composed 
by fluorescent dye Cy5.5 and biocompatible Fe3O4 NPs. This 
reasonable design allows NPs to map both the protease activity 
of MMP-9 and TME pH simultaneously, providing instant 
and quantifiable information on the local protease activity of 
MMP-9 and pH in tumors.[262]
Fluorescent QDs have become advanced contrast agents 
for efficient whole-body tumor imaging. Balalaeva et al. com-
pared the biodistribution of QDs–PEG and QDs–4D5scFv (anti-
HER2/neu scFv Abs) and found that both two QDs probes can 
be successfully applied for in vivo tumor imaging, but the fluo-
rescence signal of QDs–4D5scFv in the tumor is significantly 
stronger than that of QDs–PEG.[158] Huang et al. designed and 
synthesized NGR peptides modified QDs which could cross the 
blood brain barrier and target to CD13-overexpressed glioma 
and tumor vasculature in vitro and in vivo, contributing to FI of 
this brain malignancy.[263]
MNCs with excellent physical and chemical properties are 
also an ideal scaffold for new chemical sensors and biological 
imaging probes. Sun et al. artificially designed AgNCs–Apt 
hybrids as a specific marker of the nucleus, the confocal image 
showed that the AgNCs–Apt hybrids were mainly distributed in 
the nucleus of living cells.[175] Wang et al. found that cancerous 
cell incubated with micromolar chloroauric acid solutions 
could spontaneously biosynthesize AuNCs affording precise 
cell imaging which does not happen in normal cells, as dem-
onstrated by human embryonic liver cells. In addition, injecting 
subcutaneously chloroauric acid solution around xenograft 
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Table 2. Biomedical imaging modalities.
Imaging media Advantage Disadvantage Probes Refs.
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PAI Ultrasonic High tissue penetration
High resolution










Not suitable for gas containing organs
Diagnostic accuracy has many influ-
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Gas-NPs [314]
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PTI Infrared radiation Temperature sensitivity
Real-time monitoring
Limited spatial resolutions Photothermal materials [317]
RI Raman scattered light High resolution
Fast scanning speed
Avoiding autofluorescence of tissue
Qualitative, quantitative, and positioning analysis
Poor tissue permeability
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tumors allowed to effectively synthesize fluorescent AuNCs 
with bright fluorescence without the same effect in normal 
tissues.[264]
As UCNPs have emerged as a new class of fluorescent 
probes for biomedical imaging, different strategies have 
been studied for nanodiagnostics, such as FA-functionalized 
Gd2O3:Eu3+ NPs,[265] CEA Abs conjugated UCNPs,[266] aptamer-
templated NaGdF4:Ce3+, or Eu3+ NPs.[267] Photoluminescent 
CDs have attracted ever-increasing interest because of alluring 
properties such as excellent biocompatibility, water solubility, 
superior cell membrane permeability, high photostability, and 
tunable surface functional groups. Zheng et al. synthesized a 
new type of CDs, which could penetrate the blood-brain bar-
rier and precisely target glioma tissue with the glioma/normal 
brain ratio of 1.42.[24] Fan et al. reported pH-responsive fluo-
rescent graphene quantum dots (pRF–GQDs) with low toxicity 
and a fluorescence transition in response to the acid TME.[218]
SPNPs are a new class of organic optical nanomaterials with 
advantages of excellent optical properties, high photostability, 
facile surface functionalization, and good biocompatibility for 
biomedical optical imaging applications.[271] Distinct from inor-
ganic NPs like QDs and MNCs, SPNPs are mainly composed 
of optically active semiconducting polymers (SPs) and amphi-
philic polymer matrixes (optional). Zhu et al. designed SPNPs 
with core SPs, middle silica layer, and outer PEG corona for 
enhancing the in vivo NIR fluorescence molecular imaging. 
Multilayered nanostructures not only allow the lymph nodes 
tracking but also allow for sensitive tumor imaging.[269,272] Chao 
et al. designed SPNPs via self-assembling from an amphiphilic 
semiconducting oligomer (ASO) for photoacoustic and fluores-
cence dual-modal imaging. The fluorescent intensity of tumor 
area increased gradually with time after tail vein injection of 
ASO, which suggests that ASO passively targeted to the tumor 
site by EPR effect.[270]
The concept of biosensors was proposed in the 1960s, and 
comprehensively and deeply researched in the 1980s.[273] The 
nanofluorescent biosensor is a new analytical system that uses 
fluorescent nanomaterials as carriers with the fluorescent signal 
as the detection object. As we mentioned above, a wide variety 
of FNPs show the superior optical properties, such as bright 
fluorescence, high photostability, and excellent biocompatibility 
to be applied for the construction of fluorescent biosensor plat-
forms.[15,274] For example, Shi et al. designed a nanomedicine, 
called “sense-act-treat” system, which combined a ratiometric 
pH sensor with therapeutic gold nanocage. This design could 
“sense” the tumor through two-state switching of fluorescence 
and further provide chemotherapy and hyperthermia for tumor 
treatment, showing the future potential application in cancer 
diagnosis and therapy.[275] Saranya et al. designed smart pro-
grammable nanoarchitectures based on AuNPs linking with 
Raman-active fluorophores through a peptide linker, Phe-Lys-
Cys (FKC). The FKC was engineered with a cathepsin B (cathB) 
enzyme cleavage site for homing to cancer cells resulting in an 
on–off switching between the fluorescence and Raman modali-
ties, which can be utilized for simultaneous detection of lung 
cancer.[276] Ding and Tian developed a ratiometric fluorescence 
biosensor based on AuNCs–FA for targeted imaging and moni-
toring pH changes of cancer cells.[277] Thioredoxin reductase 
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Figure 8. FI applications of FNPs. a) C18–PMH–mPFG SWNTs. Reproduced with permission.[257] Copyright 2012, American Chemical Society. 
b) GS–AuNP. Reproduced with permission.[239] Copyright 2013, American Chemical Society. c) PEG–AuNPs. Reproduced with permission.[240] 
Copyright 2018, Wiley-VCH. d) 6PEG–Ag2S QDs. Reproduced with permission.[250] Copyright 2012, Wiley-VCH. e) DCNPs–L1/L2–FSHβ. Reproduced 
under the terms of the CC-BY Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).[232] Copyright 
2018, The Authors, Published by Springer Nature. f) InAs/InP/ZnSe QDs. Reproduced with permission.[258] Copyright 2010, American Chemical Society. 
g) UCNPs@PAA–DNA. Reproduced with permission.[109] Copyright 2018, The Royal Society of Chemistry. h) RClosed-YSA NPs. Reproduced under 
the terms of the CC-BY Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).[259] Copyright 2018, 
The Authors, Published by Springer Nature.
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(TrxR) is a redox regulating enzyme of which high levels are 
associated with the progress of tumors. Therefore, Sidhu et al. 
used CDs as analytical tools for sensing of TrxR and screening 
and detecting cancer cells.[278] Therefore, the design of FNPs for 
biosensors could integrate clinically relevant diagnostic modali-
ties for the multiplexed detection of cancer showing a bright 
future and prospects.
4.2. Cancer Drug Delivery and Therapy
Nanomaterials have obvious advantages in the targeted delivery 
of chemotherapy drugs and genes. Through the active or passive 
targeting of nanomaterials, drugs or genes carried by nano-
materials can be enriched in tumor tissues, thus increasing 
the concentration of the drug, prolonging the action time, 
protecting genes from being destroyed and reducing the toxic 
as well as side effects of normal tissue cells. Controlled drug 
delivery systems have several advantages over traditional phar-
maceutical formulations. These can urge drug transportation to 
the intended destination in the body minimizing its impact and 
harmful effects on healthy tissue. Such form of delivery is most 
important in case of drugs with a very narrow therapeutic index 
or if the drug itself is a toxic compound. At present, FL dye-
doped NPs, QDs, MNCs, UCNPs, FCNMs are the antitumor 
nanomaterials applied for optical cancer therapy. We have statis-
tically analyzed the antitumor efficiency (AE) of different FTNPs 
based on diverse targeting strategy. These data are mentioned 
in the reference article or calculated by us as shown in Table 3.
Multifunctional DOC/AS1411/Cy5.5 NPs are designed for 
cancer targeting therapy. According to their result, these MFNPs 
containing drugs have an excellent ability for cancer targeting 
and drugs delivery in a controlled fashion with powerful and 
effective antitumor efficacy of 79.55% in vivo.[215] Wu et al. 
reported a NIR prodrug DCM-S-CPT loaded in PEG–PLA NPs 
that show antitumor activity of 96.4%, higher than free CPT, 
and is also retained longer in the plasma.[279] Another group 
also applied a new kind of biocompatible and tumor-targeting 
magneto-gold@fluorescent polymer nanoparticle (MGFs-LyP-1) 
as drug delivery system. There is clear and convincing evidence 
that synthetic MGFs-LyP-1 can induce true autophagy, thus pro-
viding a certain synergistic effect by enhancing autophagy flux 
and enhancing DOX cancer treatment at non-toxic concentra-
tions.[280] Wu et al. used InP nanocomposite functionalized by 
VEGFR2 mAb for targeted drug delivery. As the in vivo experi-
ment, only the mice treated with IMAN showed strong near-
infrared fluorescence intensity and concentrated marker area, 
which completely focused on the tumor site because of the Ab 
active targeting.[213] Zhang et al. used GSH-capped red fluo-
rescent AuNCs for rapid tumor bioimaging and photothermal 
treatment. According to their result, the as-prepared AuNCs 
possessed strong fluorescence emission and excellent bio-
compatibility for in vitro cell imaging and in vivo bioimaging 
of tumors and combined with porphyrin derivatives for photo-
thermal therapy can effectively inhibit tumor growth.[281] Chen 
et al. have successfully developed a nanoplatform of AuNCs 
functionalized by cRGD and Apt for dual-targeting tumor image 
and therapy. The AuNCs were further modified by NIR fluo-
rescence dye (MPA) obtaining a NIR fluorescent dual-targeting 
probe AuNC–MPA–cRGD–Apt, which displays low cytotoxicity 
and favorable tumor-targeting capability for tumor imaging. 
Additionally, they designed a pro-drug AuNC–DOX–cRGD–
Apt by immobilizing DOX onto AuNC–cRGD–Apt to enhance 
tumor therapy efficacy.[141] Idris et al. used photosensitizers 
loaded into mesoporous-silica-coated UCNPs as a PDT agent 
for the first demonstration, conjugated with FA and PEG on 
the surface for in vivo targeted PDT. Indeed, from their studies, 
dual encapsulation of MC540 and ZnPc photosensitizers in 
UCNPs enhanced the therapeutic efficacy of PDT. Additionally, 
active targeting of the UCNPs complex to tumors by FA modi-
fying has an important role in improving the PDT therapeutic 
efficacy in tumor-bearing mice.[282] Ai et al. presented a TME-
sensitive strategy based on the enzyme-responsive cross-linking 
of rare-earth UCNs (CRUN) for tumor localization, upon the 
tumor-specific cathepsin protease reactions. To obtain the thera-
nostic efficacy, Ce6 was chosen as an effective photosensitizer 
to couple to the PEI/PAA@UCNs, namely as Ce6-modified 
UCNs. As result of PDT therapeutic effect of CRUN in living 
mice, compared with the control of NCRUN (noncrosslinking 
Ac-FKC (StBu) AC sequence modified particles) and saline, indi-
cated that the CRUN with NIR light irradiation could enhance 
the tumor therapy outcomes.[283] Yang et al. first successfully 
used PEGylated nanographene sheets (NGS) for efficient in vivo 
photothermal therapy by intravenous administration. First, they 
studied the in vivo behavior of NGS in tumor-bearing mice by 
in vivo FI and found highly efficient tumor accumulation due to 
the EPR effect. Additionally, NGS has been proven to be an excel-
lent near-infrared photothermal therapy agent for tumor with no 
obvious toxicity to mice.[284] Li et al. investigated a C6-8 Apt con-
jugated with fluorescent CDs that could inhibit the tumor cell 
growth in vitro and in vivo by targeting heterogeneous nuclear 
ribonucleoprotein (hnRNP) A2/B1. C6-8-Apt–CDs significantly 
inhibited the tumor cell proliferation both in vitro and in vivo, 
which indicated its potential for the application in cancer diag-
nosis and therapy.[285] Recently, Zhao et al. prepared a multi-
stage responsive theranostic nanoplatform including a cleavable 
PEGylated shell and a CD-based core, which exhibited effective 
accumulation at tumor sites due to elevated the EPR effect and 
TME trigger. The cascaded responsive property endows multiple 
advantages of long circulation time, effective tumor accumula-
tion, and gene-controlled release ability, which finally enhanced 
biocompatibility and cancer therapeutic efficiency.[286]
AuNCs were first conjugated with methionine (Met) and 
MPA, a NIR fluorescent dye, originating a probe of Au–Met–
MPA by Chen et al. Second, doxorubicin, a widely used clinical 
anticancer drug, was immobilized on the Met-modified AuNCs 
to form a prodrug, Au–Met–DOX. The study confirmed the 
much stronger therapeutic efficacy and tumor suppressing 
effect of Au–Met–DOX when compared with free DOX and 
Au–DOX.[287] Yang et al. designed Cy5.5-labeled WS2-IO@
MS–PEG by preadsorption with iron oxide (IO) NPs on WS2 
nanosheets and then coated with silica shell and PEG as nan-
odrug delivery of DOX triggered by NIR-induced photothermal 
heating for enhanced cancer cell killing. As demonstrated 
in in vivo experiments, the photothermal and chemotherapy 
synergistic therapeutic effect of WS2-IO@MS–PEG/DOX was 
obviously superior to monotherapies. Wang et al. developed 
a novel type of fluorescent core–shell hybrid nanocomposite 
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incorporating rare-earth Yb3+ and Er3+ ion-doped GdOF as the 
shell and gold nanorods (GNRs) as the core, creating GNRs@
GdOF: Yb3+, Er3+. Based on the evidence of in vitro and in vivo 
studies, compared with the pure GNRs, the GNRs@GdOF:Yb3+, 
Er3+ core–shell structure has better biocompatibility and cancer 
killing ability.[288]
4.3. Fluorescence-Guided Surgery
Surgery is an effective way to remove solid tumors, and 50 per-
cent of cancer patients undergo surgery each year worldwide. 
However, surgical procedures present different challenges, 
including identifying small lesions, locating metastases, and 
integrating complete tumor resection. In order to improve 
the accuracy of surgery, fluorescence guidance is a desirable 
method. Over the past decade, we have witnessed the rapid 
development of solid tumor fluorescence molecular imaging 
in tumor diagnosis and image-guided surgery. With the rapid 
development of nanotechnology, intraoperative tissue FI 
technology with fluorescence nanoprobes has become the main-
stream of tumor surgery therapy, which could greatly improve 
the accuracy of tumor resection and surgical success rate.
Preclinical development of FNPs formulations has made 
great advances, with strategies ranging from passive targeting 
to active targeting of cell surface receptors and TME responsive 
targeting, increasing cell uptake through cleavable proteins.[289] 
These joint efforts may lead to clinical trials using FNPs in the 
near future. Different from traditional anatomical and mole-
cular imaging technologies, FI technology has the advantages 
of high safety, high spatial resolution, and strong real-time 
performance, and has become a highly applicable imaging 
method for clinical tumor detection and image-guided surgery. 
In current fluorescence image-guided surgery practice, long 
tumor retention period with photostable probes is essential for 
the following precision imaging-guided resection. The effective 
Adv. Mater. 2019, 31, 1902409
Table 3. Antitumor efficiency of FTNPs based on diverse targeting strategy.
Type Targeting strategy Core structure Surface Size AE [%] Refs.
FL-dye doped NPs EPR ICG–EPI NPs Epirubicin 80–100 nm 100 [319]
Chitosan-based NPs Cy5.5/paclitaxel 250 nm 87.5 [320]
WS2–IO@MS–PEG Cy5.5/DOX 568.03 m2 g−1 92.3 [321]
PEGylated dendrimer Cy5.5/PTX 69 nm 84.5 [322]
PEG–PLA ICG/DCM-S-CPT 79 nm 96.4 [279]
EPR&AT DOC Cy5.5/AS1411 90 nm 79.6 [215]
MnO2 NPs HA/ICG 35 ± 2.5 nm 100 [323]
Fe3O4–Au NIR775/LyP–1/DOX 15–25 nm 63.2 [280]
Black phosphorus FA/Cy7 15–40 nm 100 [324]
IR825 HA/Cy5.5/PFOB 100 ± 10.7 nm 98.9 [325]
ICy5 RGD/CPT 90 nm 77.5 [326]
EPR&AT&TME LHRH-HA Cy5.5/DOX 100–150 nm 82.9 [327]
AT ICG–PL–PEG ICG/mAb 21.5 nm 70 [169]
HA–NGs Cys/cytochrome c 100 nm 80 [126]
QDs EPR Si QDs–MnO2 BSA Ce6 2 nm 89.1 [220]
EPR&AT TMPyP–Zn–QD R6G/NIR775/FA 42 nm 91.2 [328]
Ag2Se QDs Cetuximab 2.8 ± 0.5 nm 42.3 [329]
InP QDs mAb/miR-92a 7 nm 66.7 [213]
MNCs EPR AuNCs Cy5.5/U11 peptide 53 nm 100 [330]
EPR&AT AuNCs MPA 5.6 nm 64.1 [287]
AuNCs TSPP 2 nm 72.7 [281]
UCNPs EPR NaGdF4 Au25 40 nm 100 [331]
EPR&AT UCNPs FASOC/ZnPc 50 nm 82.2 [207]
Si-UCNPs FA/ZnPc 100 nm 72.4 [282]
EPR&TME UCNPs Enzyme-responsive peptide/Ce6 110 nm 70.9 [283]
FCNMs EPR FCNs siRNA 10–20 nm 90.9 [332]
SWCT Evans blue/Ce6 – 100 [333]
Carbon dots – 10 nm 100 [334]
EPR&AT Carbon dots Aptamer 25 ± 5 nm 65.7 [285]
EPR&TME HPAP-CDs pDNA 34.3 nm 70.8 [286]
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Figure 9. A transistor-like pH nanoprobe for tumor detection and image guided surgery: a) Schematic of pH nanotransistor switch at a transition pH 
of 6.9; b) SPY Elite clinical camera imaging of a variety of tumor models after 24 h injection of PINS; c) Surgical resection of primary HN5 tumors. 
a–c) Reproduced with permission.[217] Copyright 2013, Springer Nature.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1902409 (22 of 31)
www.advmat.dewww.advancedsciencenews.com
Adv. Mater. 2019, 31, 1902409
Figure 10. a) Visual assessment of the biological distribution of HFR–eNPs and the feasibility of using HFR–eNPs for cytoreductive surgery. Repro-
duced with permission.[290] Copyright 2017, American Chemical Society. NIR-II image-guided ovarian metastasis surgery: b) Schematic illustration of 
NIR-II nanoprobes; c) optical photo of human ovarian adenocarcinoma peritoneal metastases model; d) H&E staining results of tumor margin marked 
up above. b–d) Reproduced with permission.[232] Copyright 2016, Springer Nature.
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image-guided surgery strategy with high tumor-to-normal 
tissue (T/N) ratio and long tumor retention are the prerequisite 
to intraoperatively visualize the contrast between tumor nidus 
and normal tissue in real time.
In recent years, a series of tunable ultra pH-sensitive (UPS) 
nanoprobes have been developed for a wide range of biomed-
ical imaging applications, including quantitative endolysosomal 
imaging, tumor detection, and image-guided surgery as pH 
imbalance is becoming another recognized common feature of 
cancer due to tumor metabolic disorders.[217,218,260] To visualize 
tumors in vivo, a pH-activatable indocyanine green-encoded 
nanosensor (PINS) was employed as a kind of chemical tran-
sistor with a sensitive switch of pH response. It is similar to 
electronic transistor gate control to distinguish the small pH 
difference with a transition pH at 6.9 in Figure 9a.[217] A clinical 
SPY Elite camera can observe the bright tumor illumination 
observed in a wide variety of tumor models after 24 h of PINS 
intravenous injection that may be due to the EPR effect in solid 
tumors as shown in Figure 9b. By targeting to dysregulated 
pH in tumor, PINS has shown broad tumor specificity in a 
variety of cancer types, which significantly improved accuracy 
in real-time image-guided tumor resection by accurate tumor 
margin delineation as demonstrated by higher overall survival 
rate compared with white light surgery. Surgical removal of the 
HN5 primary tumor is depicted in Figure 9c, indicating that the 
SPY Elite camera can successfully detect residual tumors.
So far, the treatment of metastatic peritoneal carcinoma 
remains a major challenge and is directly correlated with com-
plete resection of primary tumor. As residual microtumors can 
lead to fatal recurrence and metastasis, in order to improve 
operative successful rate, Colby et al. designed and synthesized 
highly fluorescent rhodamine-labeled expansile NPs (HFR-
eNPs) as the visual aid during resection surgery of pancreatic 
carcinomatosis with high tumor specificity (99%) and high sen-
sitivity (92%) as shown in Figure 10a.[290] Recently, to improve 
the image-guided surgery for metastatic ovarian cancer and 
overcome the local recurrence, Wang et al. designed the NIR-II 
emitting DCNPs, which is superior to ICG with good photo-
stability and deep tissue penetration. To investigate the poten-
tial application for intraoperative imaging of DCNPs, the optical 
photo of human ovarian adenocarcinoma peritoneal metastases 
model with administrated DCNPs was observed, and found that 
either the large tumor boundary or invisible small metastatic 
lesion could be identified by NIR-II fluorescence bioimaging 
when optimal tumor surgery exhibited in the Figure 10b,c.[232]
5. Perspective and Outlook
With the progress of materials science, spectroscopy and 
microscopy, the state of the art of FI is impressive. In view of 
the summary of many literatures, we found that the EPR effect 
is still the mainstream to design nanocarriers. However, the 
conclusion has been drawn from the past decades research 
that the EPR effect works in rodents, but not in humans beings 
because of the pretty low targeting efficacy.[41] Therefore, sci-
entists began to intensify the active targeting and TME study 
to make up for the deficiency of the EPR effect. CMPT is a 
new targeting mechanism proposed by Wang’s group.[37] The 
designed nanoprobe can discern tumor cells from normal 
cells through the differences of cell membrane permeability 
between the two cell types. These probes can recognize tumor 
tissue in a very early stage and track the invasion and metas-
tasis of tumor cells at the single cell level. More importantly, the 
tumor targeting rate can be improved to as high as 50%. It can 
guide the design of new nanocarriers and open new avenues 
for tumor diagnosis and treatment. At the same time, with the 
concept of “precision medicine” introduced by Obama in 2015, 
researchers have developed some new ideas and methods for 
cancer treatment and have made some progress.[291] Immu-
notherapy has come to the forefront of cancer treatment. In 
immunotherapy, drugs enable the body to naturally attack 
abnormal cancer cells by activating the immune system, which 
improves the tumor-specific targeting.[292,293] Checkpoint inhibi-
tors are common strategies. The two most common checkpoint 
inhibition strategies are programmed cell death 1 (PD-1) /PD-1 
ligand 1 (PD-L1) blockade and cytotoxic T lymphocyte antigen 
4 (CTLA4) inhibition. For example, when T cells are activated, 
they express PD-1, which can recognize cancer cells. How-
ever, tumor cells express PD-L1 to avoid being recognized and 
cleared by T cells. Binding of PD-1 to PD-L1 could inactivate T 
cells. Thus, blocking this interaction with mAb targeting PD-1 
or PD-L1 can trigger T-cell-mediated tumor cell death.[292,294] 
CTLA4 is a molecule that regulates the activation of T cells. 
The interaction of CTLA4 with CD80 and CD86 inhibits 
T cell activity and promotes tumor progression. By blocking 
the interaction between CTLA4 and these ligands, T cells main-
tain the ability of identifying and killing tumor cells.[292,295] A 
drug targeting CTLA4 was used to treat advanced melanoma in 
2011.[296] Recently, a new immunological method called chimeric 
antigen receptor T (CAR-T) cell therapy has attracted people’s 
attention. CAR-T works by collecting T cells from a patient’s 
blood and then modifying them to express antigen-specific 
T-cells present on tumor cells. The modified T cells are then 
reinjected into the same patient. After injection, CAR T cells 
recognize target antigens on tumor cells and induce tumor cell 
death.[297] CAR-T has achieved some clinical successes, with 
many patients achieving prolonged survival.[292] One population 
of tumor-inducible, erythroblast-like cells (Ter-cells) deriving 
from megakaryocyte-erythroid progenitor cells are studied pro-
viding a new research idea for the development and invasion of 
tumors, as well as a potential drug research target for the study 
of complex tumor.[298] Yan et al. and her group first found the 
mechanism of the role of CD146 in regulating human mela-
noma cell motility, namely that CD146 physically interacts with 
ezrin radixin moesin (ERM) proteins and recruits ERM pro-
teins to cell protrusions, promoting the formation and elonga-
tion of microvilli.[299] In recent years, nanomaterials combined 
with immunotherapy have been shown to improve the efficacy 
of anticancer and immunomodulatory drugs.[300] Yang et al. got 
the endogenous vaccination by combining DOX with chlorine 
e6 in hollow MnO2 NPs. MnO2 NPs react with hydrogen per-
oxide in the TME and alleviating local immunosuppression 
and improving the efficacy of tumor immunotherapy. After the 
degradation of MnO2 NPs, chlorine e6 mediated PDT.[301] Liu 
and co-workers combined PLGA nanoparticles with ICG and 
TLR7/8 agonist imiquimod, which is a potent immune costim-
ulating agent. This compound system improved the therapeutic 
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effect of CTLA4 under the irradiation of NIR.[302] Nam et al. 
synthesized spiky Au nanoparticles coated with polydopamine 
to enable local PDT. It is worth mentioning that PDT treat-
ment can generate adoptive immunity. All the mice treated by 
PDT survived after second injected of C26 cancer cells, but the 
unexposed mice died within 35 days.[303] These studies suggest 
that the combination of nanomaterials and immunotherapy is a 
promising approach to cancer treatment.
As mentioned above, TME is very complex, with abnormal 
vascular structure, interstitial fluid pressure and other factors 
hindering drug delivery. Furthermore, vascular abnormali-
ties facilitate immune evasion. Jain and co-workers have been 
working on improving drug delivery through the regulation 
of tumor blood vessels and TME. They have achieved a 
series of successes. For example, in an ovarian cancer model, 
chemotherapy was improved by normalizing the tumor stroma 
and reducing ascites.[304] They improved the drug efficacy by 
reengineering the tumor vasculature.[305] Normalization of 
tumor blood vessels can increase tumor infiltration and trans-
formation by immune effector cells.[306] Therefore, combina-
tion with antiangiogenesis treatment and immunotherapy may 
improve outcomes.
Biomolecular recognition, nanobiosensor, nanorobot, com-
putational biology methods, drug action mechanism studies 
also contributed a lot to improve the cancer therapy and 
diagnosis.[307] Another novel tumor targeting strategy is the 
pathway-based targeted therapy. The goal is to regulate an 
abnormal protein or critical pathway to cancer survival. With 
the development of genetic engineering and proteomics, it is 
possible to analyze human proteins and genes, which provides 
a basis for screening new tumor therapeutic targets. These 
methods often use gene sequencing and other methods to 
screen new targets for cancer treatment. Recently, many new 
tumor therapeutic targets have been discovered through this 
method with remarkable results.[308,309]
Improving the therapeutic effect on cancer, prolonging the 
life of patients and reducing the toxicity and side effects are 
the goals that researchers have been pursuing. To this end, sci-
entists have been making continuous efforts. The new design 
mechanism and strategies give new ideas for cancer treatment 
whether the immunotherapy, proteomics, or our newly discov-
ered CMPT mechanism. At the same time, some countries 
have begun to pay attention to the early prevention of cancer. 
A primary mode of cancer prevention and early detection in 
the United States is the widespread practice of screening. The 
fighting against cancer has always existed. We believe that 
we will eventually find the way to conquer the cancer with 
the continuous efforts and the discovery of new methods and 
mechanisms.
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